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Clustered regularly interspaced short palindromic repeat (CRISPR)
loci and their associated (Cas) proteins provide adaptive immunity against
viral attack in prokaryotes. Upon infection, short phage sequences known as
spacers integrate between CRISPR repeats and are transcribed into small
RNA molecules that guide the Cas9 nuclease to the viral targets
(protospacers). Streptococcus pyogenes Cas9 cleavage of the viral genome
requires the presence of a 5′-NGG-3′ protospacer adjacent motif (PAM)
sequence immediately downstream of the viral target. Before my graduate
work, it was not known whether and how viral sequences flanked by the
correct PAM are chosen as new spacers. My work revealed that Cas9
selects functional spacers by recognizing their PAM during spacer
acquisition. The replacement of cas9 with alleles that lack the PAM
recognition motif or recognize an NGGNG PAM eliminates or changes PAM
specificity during spacer acquisition, respectively. Cas9 associates with
other proteins of the acquisition machinery (Cas1, Cas2 and Csn2),
presumably to provide PAM-specificity to this process. This was a newly
identified function of Cas9 in the genesis of prokaryotic immunological
memory.

To further explore the link between Cas9 and spacer acquisition, I
performed random mutagenesis of the RNA-guided Cas9 nuclease to look for
variants that provide enhanced immunity against viral infection. I identified a
mutation, I473F, which increases the rate of spacer acquisition by more than
two orders of magnitude. This patented variant of Cas9 highlights the enzyme’s
role during CRISPR immunization, provides a useful tool to study this
otherwise rare process, and holds promise to be developed into a
biotechnological application.

Researching Cas9 and spacer acquisition involved many rounds of
high-throughput sequencing of millions of spacers acquired by bacteria during
phage infection. These experiments revealed that the abundance of each
spacer in the surviving population was highly uneven. Since the molecular
mechanisms underlying this bias were not known, I decided to look into the
factors that affect the distribution of individual spacer sequences during phage
infection of cells harboring the CRISPR system from Streptococcus pyogenes.
My work has shown that spacer patterns are established early during infection
and correlate with spacer acquisition rates, but not with spacer targeting
efficiency. The data suggests that the rate of spacer acquisition depends on
unique sequence elements within the spacers and therefore determines the
abundance of different spacers within the adapted population. These results
elucidate a fundamental mechanism behind the generation of immunological
diversity during the type II CRISPR-Cas response.
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Chapter I.
Introduction

Clustered, regularly interspaced, short palindromic repeats (CRISPR) loci
and their associated genes (cas) confer bacteria and archaea with adaptive
immunity against phages and other invading genetic elements. A fundamental
requirement of any immune system is the ability to build a memory of past
infections in order to deal more efficiently with recurrent infections. The adaptive
feature of CRISPR-Cas immune systems relies on their ability to memorize DNA
sequences of invading molecules and integrate them in between the repetitive
sequences of the CRISPR array in the form of ‘spacers’. The transcription of a
spacer generates a small antisense RNA that is used by RNA-guided Cas
nucleases to cleave the invading nucleic acid in order to protect the cell from
infection. The acquisition of new spacers allows the CRISPR-Cas immune
system to rapidly adapt against new threats and is therefore termed ‘adaptation’.
Recent studies have begun to elucidate the genetic requirements for adaptation
and have demonstrated that rather than being a stochastic process, the selection
of new spacers is influenced by several factors. This chapter reviews our current
knowledge of the CRISPR adaptation mechanism.
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Chapter 1.1. Overview of CRISPR Immunity
Bacteria and archaea have evolved to thrive in hostile environments under
the constant threat of viral (phage) attack. As a result, these organisms have
devised numerous strategies to prevent phage infection, including abortive
infection, surface exclusion and restriction modification systems1,2. While highly
effective, these innate defense strategies provide non-specific immunity. In
contrast, the CRISPR-Cas immune system provides an adaptive defense
mechanism against phages and other mobile genetic elements3–5.
Since their discovery in Escherichia coli in 19876, CRISPR systems have
proven to be widespread among bacteria and archaea7–9. Generally, a CRISPR
locus contains the CRISPR-associated (cas) genes and the CRISPR array. The

cas genes encode a diverse family of Cas proteins carrying predicted functional
domains of proteins that participate in nucleic acids transactions, such as DNAbinding proteins, nucleases, polymerases and helicases4,10. The CRISPR array
consists of identical nonadjacent sequences (repeats) interspaced by similarly
sized variable sequences (spacers). An AT-rich leader sequence located
upstream of the first repeat promotes the transcription of the CRISPR array11,12
and is essential for spacer acquisition. Repeats are usually conserved within the
same locus, and in most cases contain partially palindromic sequences13.
Spacers are highly diverse even among closely related strains and were
therefore initially exploited for strain typing purposes14. In 2005, independent
bioinformatics studies revealed homology between spacer sequences and mobile
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genetic elements3,15. This observation led to the hypothesis that CRISPR may
provide protection against invading phages and plasmids4. Soon, spacers were
confirmed to provide sequence-specific interference against all prokaryotic routes
of horizontal gene transfer, including bacteriophage infection5,16,17, plasmid
conjugation18 and transformation19,20.
CRISPR-Cas systems provide immunity against phages through a threestep defense pathway (Figure 1-1). First, a fragment of the invading nucleic acid
(protospacer) is incorporated into the CRISPR array along with a synthesis of an
additional repeat unit. This process is known as adaptation and is responsible for
the unique adaptive features of CRISPR5. Second, during the crRNA biogenesis
phase, the CRISPR locus is transcribed and then processed into mature guide
RNAs (crRNAs)21. Third, crRNAs recruit effector complexes and guide them to
their target by base pairing with the invading nucleic acids22. This last step of
CRISPR immunity is known as interference and ends with the cleavage of the
exogenous genetic element23. Despite this general mode of action, CRISPR
systems have been classified into six types (I-VI), each of them with several
subtypes, depending on the gene composition and architecture of the
respective cas operons24,25. While studies of the mechanisms of crRNA
biogenesis and interference are well advanced, CRISPR adaptation, also known
as immunization or spacer acquisition, perhaps the most puzzling and fascinating
aspect of these systems, remains poorly understood.
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Figure 1-1. The three stages of CRISPR immunity. CRISPR loci consist of
clusters of repeats (white rectangles) and spacers (colored rectangles) that are in
proximity of the upstream leader sequence and CRISPR-associated (cas) genes.
During adaptation, new spacers derived from the genome of the invading virus
are incorporated into the CRISPR array along with a new repeat unit. During
crRNA biogenesis, the array is transcribed, and the precursor transcript is
processed by Cas endoribonucleases in order to generate small crRNAs. During
interference, the crRNA guides a complex of Cas proteins to the matching target
to initiate nucleolytic cleavage (scissors) of the invading nucleic acid.
4

Chapter 1.2. Spacer Acquisition
Spacer acquisition was first demonstrated under laboratory conditions in
2007 for the type II-A system of Streptococcus thermophilus5. In these studies,
investigators examined the CRISPR array of phage-immunized bacteria and
found the addition of new repeat-spacer units, with all new spacers perfectly
matching regions of the genome of the challenging phage. Mutants that acquired
spacers targeting sequences shared between two phages were resistant to both
viruses. These results established CRISPR-Cas systems as an adaptive,
sequence-specific immune system against phages and were corroborated in
other bacteria and archaea containing different CRISPR-Cas Types: Escherichia

coli type I-E26–28, Pseudomonas aeruginosa type I-F29, Streptococcus agalactiae
type II-A30, Haloarcula hispanica type I-B31, and Sulfolobus solfataricus type I-A
and III-B32.

Chapter 1.2.1. The Protospacer Adjacent Motif
When investigators aligned newly acquired spacers from the S.

thermophilus CRISPR-Cas system in search for common motifs, they found
something unexpected. Instead of a common sequence within the spacers they
found a conserved sequence outside the target (also known as protospacer),
which was termed Protospacer Adjacent Motif (PAM)17. Therefore, it became
clear early on that not all phage sequences are equal for the CRISPR-Cas
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system, suggesting that the adaptation machinery only acquires spacers that
have adjacent PAMs. The PAM is not only important for the acquisition of spacer
sequences, it is also required for the interference phase of CRISPR immunity
since PAM mutations in types I and II prevent Cas nuclease cleavage17,33–36. This
interference requirement is readily exploited by phages, which can avoid CRISPR
immunity by mutating the PAM sequence17. The PAM is fundamental to avoid
auto-immunity. If CRISPR immunity relied only on base-pair interactions between
the crRNA and the target DNA, then the spacer sequence on the CRISPR array
would be a target for the crRNA as well. Since the flanking sequences of a
spacer in the CRISPR array are the CRISPR repeat, which lack a proper PAM,
auto-immunity is prevented and only protospacers that are flanked with the
correct PAM can be cleaved. Type III CRISPR-Cas systems, however, seem to
be an exception, as no PAM is evident from the alignment of protospacer
sequences acquired by these systems, nor it is required for target cleavage37,38.
As a consequence, Type III systems developed a different mechanism to prevent
auto-immunity38.
While the recognition of a PAM by the acquisition machinery is essential
for a protospacer to be selected, it appears that other mechanisms further
influence the protospacer choice. Studies of spacer acquisition by the E. coli type
I-E28,39

and the S. thermophilus type II-A40 CRISPR-Cas systems reported
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unequal distributions of protospacers across various targets. The expansion of
the CRISPR arrays from S. thermophilus was monitored using DNA deepsequencing upon infection with a lytic phage40 and roughly half a million phagederived spacer sequences were analyzed. Surprisingly, the top 10% most
overrepresented spacers accounted for 99% of the identified sequences. In
contrast, some candidate protospacers that could have been theoretically
acquired from the target based on PAM compatibility were never sampled. Due to
partial sequence similarities between some endogenous spacers and the target,
Paez-Espino et al.40 propose priming (Figure 1-2a) as a possible explanation for
the strong overrepresentation of certain protospacers. In a similar study in type IE, all potential protospacer sequences adjacent to a PAM were used as spacer
donors, but the frequencies were indeed highly unequal39. While no correlation
was observed between the frequency of protospacer incorporation and its
nucleotide sequence, melting temperature, GC content, ssDNA secondary
structure, or transcription pattern, other investigators detected additional
sequence motifs besides the PAM that influence the acquisition efficiency of a
protospacer41. By exchanging nucleotide blocks of various lengths upstream or
downstream of one high-acquisition and one low-acquisition protospacer,
investigators were able to reverse their rates of acquisition, suggesting that DNA
motifs located at both ends of the highly acquired protospacer were responsible
for its frequent incorporation. More specifically, in addition to the PAM, a
dinucleotide AA motif termed Acquisition Affecting Motif (AAM) located at the 3’
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end of the protospacer can boost the rate of incorporation of a given protospacer.
Sequences of more than two million spacers confirmed the overrepresentation of
the AA motif in highly sampled protospacers. Nonetheless, the AAM was not
present in all highly sampled protospacers, indicating that other unidentified DNA
motifs might influence the sampling frequencies of protospacers. In a different
study, the AAM was not confirmed among plasmid-derived spacers.

Chapter 1.2.2. Naïve and Primed Acquisition
Cas1 and Cas2 are the only Cas proteins universally conserved across all
types and subtypes of CRISPR-Cas systems10,24. Initial studies on the role of Cas
proteins revealed that mutations or deletions of Cas1 and Cas2 did not impact
interference and crRNA maturation in type I42, type II43,44, and type III45,46. These
observations led to the hypothesis that the two universal Cas proteins might be
involved in adaptation. Indeed, in E. coli, overexpression of both cas1 and cas2
alone in the absence of the other cas genes was sufficient to acquire new
plasmid-derived or host-derived spacers26,28. Yosef et al. (2012) also found that
Cas1/2 mediate the preferential acquisition of spacers with a correct PAM,
demonstrating that there is a mechanism to select spacer sequences flanking
this motif, as opposed to the random acquisition of DNA sequences followed by
the selection of those with correct PAMs. The biochemical properties of Cas1
support its role in spacer acquisition. Pseudomonas aeruginosa Cas1 has been
shown to bind dsDNA in a sequence-independent manner with high affinity, and
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to work as a metal-dependent endonuclease which cleaves dsDNA into short
fragments, that might serve as precursors for new spacers47,48. Nonetheless, it is
still unclear whether new spacers are cut or copied from the invading molecule.
Because Cas1 also has the ability to resolve Holliday junctions and thus promote
DNA integration and recombination events, it could promote the integration of
spacer sequences into the repeat-spacer array. While many Cas2 crystal
structures have been solved and studied biochemically49–51, a general consensus
regarding its activity has not been reached.
The Cas1/2-mediated acquisition can add repeat-spacer units to a minimal
CRISPR locus consisting of only one repeat sequence28. This indicates that this
mechanism of acquisition does not require the presence of any other spacers, i.e.
a previous exposure to the same or related phages and therefore is referred as
“naïve” acquisition. This is in contrast to “primed” acquisition, where the presence
of spacers with a full or partial match to the target DNA increases the frequency
of acquiring another spacer (Figure 1-2a).
Primed acquisition has been studied in E. coli, which CRISPR-Cas system
harbors the genes encoding the Cascade (CRISPR associated complex for
antiviral defense) complex that contains the crRNA guide and is responsible for
target recognition42 and the Cas3 nuclease responsible for target cleavage22, in
addition to Cas1 and Cas2. One study showed that this CRISPR system can
acquire spacers from a plasmid present in the cell, resulting in plasmid curing27.
While the acquisition of a single spacer is enough to cure the plasmid, multiple
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Figure 1-2. A model for the acquisition of new spacers. (a)
Naïve vs. primed spacer acquisition. Upon lytic infection with a phage previously
not encountered, incorporation of a new spacer into the CRISPR array ensures
cell survival. Only protospacers adjacent to PAMs are sampled. Naïve adaptation
(left) requires the concerted action of Cas1 and Cas2 alone. Primed acquisition
(right) presupposes the existence of a non-targeting crRNA with partial homology
to a region of the infecting phage (purple). Following the low-affinity target
recognition by the interference machinery, the complex slides along the target
DNA and, aided by Cas1 and Cas2, and recruits spacers from the same strand at
a high rate. (b) A model for spacer integration onto the CRISPR array. The
protospacer (green) is acquired from the viral genome and inserted into the
CRISPR array at the leader-proximal end. Upon integration, the first pre-existent
repeat serves as a template for the new repeat. In this model I speculate that the
palindromic sequence of the repeat allows it to fold into DNA hairpins (grey).
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spacers were frequently incorporated into the CRISPR array. Interestingly these
were always acquired from the same strand of DNA. This led to the hypothesis
that the acquisition of one spacer can trigger the acquisition of additional spacers
from the same strand of the target DNA27. These authors hypothesize that the
Cascade complex is directed to bind the foreign nucleic acid by a spacer already
present in the array. If the match is good enough to trigger interference, Cas3 will
degrade the dsDNA and these cleavage products can be used by Cas1 and
Cas2 as precursors for new spacers recruited from the same strand.
Another study reported primed adaptation during infection of E. coli with
the M13 phage26. The acquisition of new spacers was much more frequent when
a spacer already targeting the M13 phage was present in the array. The authors
showed how the orientation of the priming target determines the orientation of
new protospacers. Interestingly, priming events occurred when mismatches that
abolish interference were present between the crRNA and its target. This
suggests that degradation of the target DNA by CRISPR interference is not
necessary to prime adaptation. It is hypothesized that the Cascade complex can
bind an imperfect target and trigger the acquisition of new spacers from the same
molecule. Mutagenesis of the cas genes showed that in addition to Cas1 and
Cas2, primed adaptation requires the Cascade complex and Cas3. Subsequent
high-throughput analysis of spacer acquisition in E. coli confirmed that spacers
are preferentially acquired from the primed strand with a 10-fold bias39. Assuming
that spacers acquired from the non-primed strand are due to naïve adaptation,
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the authors conclude that primed adaptation occurs at much higher rates than
naïve adaptation. Recently, a comprehensive study performed in type I-E showed
that priming is nucleotide-dependent, as well as sensitive to the number of
mutations and their locations with the target. Accordingly, high-throughput
plasmid-loss assays revealed that priming tolerates up to 13 mutations within the
PAM and protospacer. While the nucleotide-dependence of priming appears to
be a more complex mechanism that needs to be further characterized, it appears
that G-rich spacers are more likely to prime a better adaptation response.
These observations led to the “sliding” hypothesis for primed acquisition:
after a low-affinity target recognition by the Cascade-crRNA complex, the
complex slides along the target DNA randomly stopping at PAM sequences to
recruit more spacers from the same strand (Figure 1-2a). This hypothesis was
tested by several studies with results that both corroborated or challenged it. In a
recent study of the E. coli type I-E system, Savitskaya et al.39 argue that sliding
from the priming position should lead to a preferential acquisition of nearby
spacers, producing a gradient in spacer acquisition frequency relative to the
priming location, which they did not observe. Moreover, insertion of poly-PAM
blocks on the target molecule next to the priming site failed to halt the putative
sliding acquisition machinery. Notably, these experiments were carried out on
rather short (~ 3kb) circular plasmids that might have obstructed acquisition
gradients caused by the priming site or poly-PAM brakes. In contrast, a recent
study of Haloarcula hispanica type I-B system showed that protospacers in close-
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proximity of the priming protospacers were sampled more often than
protospacers located farther away31, thus supporting the sliding hypothesis.
Regions located both upstream and downstream of the priming protospacer were
highly sampled, but from opposite strands. Therefore, the authors proposed that
sliding also involves stochastic Cas3 flipping from one strand of the DNA to the
other. These contradicting results could be explained either by the presence of
multiple priming sites or differences in the sliding dynamics, since a fast-sliding
Cascade would prevent the generation of a positional gradient of acquired
spacers.
The priming mechanism has likely evolved as a way to counteract phage
mutants that escape CRISPR immunity by single point mutations in the target
sequence. The spacers matching mutated targets cannot direct cleavage but can
still be used to trigger the acquisition of new spacers and adapt against an
evolving threat. Furthermore, priming favors the acquisition of multiple spacers
targeting the same DNA molecule, which reduces the probability of escape and
strengthens

resistance.

Notwithstanding

the

benefits

of

primed

spacer

acquisition, naïve adaptation remains crucial to detect unknown foreign
molecules and is probably a universal feature of CRISPR systems.

Chapter 1.2.3. Spacer Integration
Once a target has been selected on the invading genome, it has to be
incorporated into the CRISPR array. During this process, not only the spacer is
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incorporated, but also a new repeat is added to the array. Spacer insertion is
polar, since the vast majority of new spacers are incorporated at the 5’ end of the
array, upstream of the first repeat5,16,52–56. Little is known about this process;
however, the first repeat and the region immediately upstream of it, known as the
leader sequence, seem to play a role.
The 200-500 bp region located upstream of the first repeat contains an
A/T rich leader sequence that usually harbors the promoter of the CRISPR array,
but it is also involved in adaptation. Deleting or scrambling the 60 nucleotides
immediately adjacent to the array of the type I-E CRISPR-Cas system of E. coli
prevents spacer acquisition28. This indicates that the leader contains specific
sequence motifs essential for adaptation. Interestingly, deleting the Pribnow box
required for the transcription of the array does not prevent spacer acquisition28,
suggesting that transcription is not essential for the adaptation process. It is
believed that the leader sequence is recognized by the acquisition machinery.
Evidence supporting this hypothesis comes from a study showing that Cas1 and
Cas2 from the E. coli K12 strain can direct spacer acquisition in the CRISPR
array of the O157:H7 strain, which carries a different leader sequence57.
However, this artificial leader-Cas combination led to frequent abnormal
acquisition events where the spacers were integrated in the wrong orientation.
This suggests that the interaction between Cas proteins and the leader sequence
determines the orientation of newly acquired spacers. Furthermore, in some
instances, the insertion site was shifted by 2 bases, suggesting that the
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acquisition complex is anchored at the leader-repeat boundary where a first cut is
made, and uses a ruler mechanism to cut the other strand on the other side of
the repeat. The nucleotide content of the spacer is also thought to impact the
orientation of newly acquired spacers. In type I-E, an underrepresentation of G
and overrepresentation of C at the end of highly acquired spacers may serve as
signals for insertion in the correct orientation.
The presence of a single repeat has been shown to be necessary and
sufficient for both naïve and primed adaptation in the type I-E CRISPR
system26,58, and the presence of additional repeats does not increase the rate of
acquisition of new spacers41. Interestingly, spacers incorporated into a minimal
CRISPR array (one repeat, no preexisting spacers) have the correct length58,
suggesting that the protein machinery, rather than preexistent repeat-spacer
units, dictates the size of additional spacers. In type I-E systems, the new repeat
(29 nt long) is copied from the first repeat in the array since point mutations
introduced in the first repeat are replicated in newly incorporated spacer-repeats
units26,28. Interestingly, mutations of the last nucleotide of the repeat were not
passed on to new repeats, indicating that only bases 1 through 28 of the repeat
serve as a template for new repeats. In contrast, the 29th base originates from the
protospacer and represents the last nucleotide of the PAM26,59. While the last
nucleotide of the 5’-AWG-3’ PAM is highly conserved in E. coli, this is not the
case in many other systems where this mode of repeat duplication remains to be
determined. Based on these results and on the known mechanisms of insertion
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of transposable elements60 and retroviruses61 a model for spacer acquisition has
emerged (Figure 1-2b). The first repeat sequence of the CRISPR locus is
subjected to ssDNA nicking at the 3’ end of each repeat strand. This cleavage
could be facilitated by the stem-loop structure that can form on most repeats due
to their partially palindromic sequences. Proximity to the leader would provide
recognition of the first repeat and/or help recruit the spacer acquisition
machinery. The free 3’-ends of repeats are ligated to the 5’ end of viral
fragments, leading to the insertion of a new spacer and the generation of a
staggered intermediate. The gaps are filled by DNA polymerase I, thus adding a
new repeat to the array. Current research across different laboratories is testing
this model.

Chapter 1.3. Unanswered Questions
Although recent studies have established molecular requirements as well
as a general mechanism for the acquisition phase, many details of CRISPR
adaptation are still poorly understood. An extra layer of complexity is added by
the many different types of CRISPR-Cas systems, some of which could have
different mechanisms of spacer acquisition. Indeed, variations in the way spacers
are acquired from the target likely exist between CRISPR types and subtypes. In
the type I-A of the crenarchaeon Thermoproteus tenax, Cas1 and Cas2 are fused
as a single protein that forms the CRISPR-associated complex for the integration
of spacers (Cascis) together with Csa1 and Cas462. In type II, Csn2 was reported
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to be required for adaptation5. Structural studies have revealed that this protein
forms a ring-like structure around DNA, suggesting that it might recruit other
proteins to the protospacer and could form a sliding clamp that facilitates primed
acquisition63. In type III, interference is transcription dependent and requires
crRNAs that are antisense to their cognate RNA targets64. Since transcription of
CRISPR loci is unidirectional, type III spacers need to be incorporated into the
correct orientation in order to produce functional crRNAs. The underlying
mechanism of this requirement is not understood.
I believe that future research will focus on understanding how the leader
sequence is recognized, how the first repeat is cleaved, and the new spacer
ligated in a way that allows the generation of an additional repeat, and whether
the length of the array is regulated. In addition, it is still unknown why spacers are
acquired preferentially from certain molecules or certain positions on a given
molecule, and whether any mechanisms truly exist to prevent, or at least limit, the
of self-targeting spacers. An interesting question also arises from the
observation that the PAM motif is recognized both during acquisition and
interference, and that the motif might be recognized by different protein
complexes in each of these stages of the CRISPR immunity pathway. As the
exact sequence requirements might be different for these two functions, it has
been proposed to use the term Spacer Acquisition Motif (SAM) when referring to
the sequence recognized by the acquisition machinery and the term Target
Interference Motif (TIM) when referring to the sequence recognized by the
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interference machinery65. A mutation that affects SAM recognition might lead to
the acquisition of spacers that will not be effective during the interference stage.
Conversely, a mutation that affects the TIM recognition might render preexisting
as well as newly acquired spacers useless. In the presence of this apparent
evolutionary bottleneck, PAM sequences might be expected to be highly
conserved, yet an extensive diversity has been described. How these two facts
can be reconciled remains to be investigated.
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Chapter II.
The Role of Cas9 in Spacer Acquisition

This chapter investigates the molecular requirements of spacer
acquisition in the type II-A CRISPR system of Streptococcus pyogenes. Cas9
cleavage of the viral genome requires the presence of a 5′-NGG-3′
protospacer adjacent motif (PAM) sequence immediately downstream of the
viral target. It is not known whether and how viral sequences flanked by the
correct PAM are chosen as new spacers. Here I show that Cas9 selects
functional spacers by recognizing their PAM during spacer acquisition. The
replacement of cas9with alleles that lack the PAM recognition motif or
recognize an NGGNG PAM eliminated or changed PAM specificity during
spacer acquisition, respectively. Cas9 associates with other proteins of the
acquisition machinery (Cas1, Cas2 and Csn2), presumably to provide PAMspecificity to this process. This chapter introduces a new function for Cas9 in
the genesis of prokaryotic immunological memory.
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2.1. The Protospacer Adjacent Motif is Highly Conserved
Based on their cas gene content, CRISPR-Cas systems can be classified
into six distinct types, I-VI24,25. Each CRISPR-Cas type possesses different
mechanisms of crRNA biogenesis, target destruction and prevention of
autoimmunity. In the type II CRISPR-Cas system present in Streptococcus
pyogenes the Cas9 nuclease inactivates infective phages using crRNAs as
guides to introduce double-strand DNA breaks into the viral genome23. Cas9
cleavage requires the presence of a protospacer adjacent motif (PAM) sequence
immediately downstream of the protospacer34,67. This requirement avoids the
cleavage of the spacer sequence within the CRISPR array, i.e. autoimmunity,
since the adjacent repeat lacks a PAM sequence. The importance of the PAM
sequence for target recognition and cleavage34,67–69 suggests the presence of a
mechanism to ensure that newly acquired spacer sequences match protospacers
flanked by a proper PAM sequence. For the type I-E CRISPR-Cas system of
Escherichia coli, over-expression of cas1 and cas2 is sufficient for the acquisition
of new spacers in the absence of phage infection. Reports indicate that spacers
acquired in this fashion match preferentially (25–70%, depending on the study) to
protospacers with the correct PAM (AWG, W=A/T)26,28,57,70, suggesting that Cas1
and Cas2 are sufficient for spacer acquisition and have some intrinsic ability to
recognize protospacers with the right PAM. In the type II system of S. pyogenes
the PAM sequence is NGG (and also NAG at a much lower frequency)4,33,34,
where N is any nucleotide, and it is recognized and bound by a domain within the
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Cas9 tracrRNA:crRNA-guided nuclease during target cleavage67,71. How spacers
are acquired in this system, particularly how spacers with correct PAM
sequences are selected during this process, is not known.

2.2. Cas9 is required for spacer acquisition
To

investigate

the

mechanisms

of

recognition

of

PAM-adjacent

protospacers during spacer acquisition, Icloned the type II-A CRISPR-Cas locus
of S. pyogenes (Figure 2-1a) into the staphylococcal vector pC194 and
introduced the resulting plasmid64 into Staphylococcus aureus RN422072, a strain
lacking CRISPR-Cas loci. Ichose this experimental system because it facilitates
the genetic manipulation of the S. pyogenes CRISPR-Cas system. Ifirst tested
the ability of the cells to mount adaptive CRISPR immunity by infecting them with
the staphylococcal phage ϕNM4γ4, a lytic variant of ϕNM473 (see Methods for a
description of ϕNM4γ4 isolation).
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Figure 2-1. Cas9 is required for spacer acquisition. (a) Organization of
the S. pyogenes type II-A CRISPR-Cas locus. Arrows indicate the annealing
position of the primers used to check for the expansion of the CRISPR array. (b)
PCR-based analysis of cultures to check for the acquisition of new spacer
sequences. In the presence or the absence of phage φNM4γ4 infection. Wild-type
(WT) as well as different cas mutants were analyzed. MOI; multiplicity of
infection. (c) Cultures over-expressing Cas1, Cas2 and Csn2 under the control of
a tetracycline-inducible promoter were analyzed using PCR for spacer acquisition
in the absence of phage infection. The strain was complemented with plasmids
carrying either Sp or St Cas9 (see Fig. S3). aTc; anhydrotetracycline.

Plate-based assays performed by mixing bacteria and phage in top agar
allowed the selection of phage-resistant colonies that were checked by PCR to
look for the expansion of the CRISPR array (Figure 2-2a). On average 50 % of
the colonies acquired one or more spacers (8/13, 5/11 and 7/16 in three
independent experiments), whereas the rest of the resistant colonies survived
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phage infection by a non-CRISPR mechanism, most likely including phage
receptor mutations (Figure 2-3a). To maximize the capture of new spacer
sequences, Iperformed the same assay in liquid and recovered surviving bacteria
at the end of the phage challenge. These were analyzed by PCR of the CRISPR
array and the amplification products of expanded loc I was subjected to Illumina
MiSeq sequencing to determine the extent of spacer acquisition. Analysis of 2.96
million reads detected protospacers adjacent to 2083 out of 2687 NGG
sequences present in the viral genome, although with variation in the frequency
of acquisition of each sequence (Figure 2-2b). The data revealed a prominent
selection of spacers matching protospacers with downstream NGG PAM
sequences (99.97 %, Figure 2-2c). The acquisition of new spacers by cells in
liquid culture proved to be simple and highly efficient, providing the possibility to
look at millions of new spacers in a single step. It was therefore implemented in
the rest of our studies.
To determine the genetic requirements for spacer acquisition Imade
individual deletions of cas1, cas2 or csn2 and challenged the mutant strains with
phage ϕNM4γ4. Spacer acquisition was decreased to levels below our limit of
detection in each of these mutants (Figure 2-1b), corroborating previous
experiments26,43. Therefore, while Cas1, Cas2 and Csn2 are dispensable for antiphage immunity in the presence of a pre-existing spacer (Figure 2-3b and c),
they are required for spacer acquisition.
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Figure 2-2. The S. pyogenes type II CRISPR–Cas system displays a
strong

bias

for

the

acquisition

of

spacers

matching

viral

protospacers with NGG PAMs. (a) Analysis of bacteriophage-insensitive
mutant colonies using PCR and agarose gel electrophoresis, representative of
five technical replicates. Bacteria and phage were mixed in top agar and
incubated overnight. DNA was isolated from individual colonies resistant to
phage infection and used as template for a PCR reaction with primers (arrows)
H182 and H183, which amplify the end of the S. pyogenes CRISPR array. The
size of the PCR band indicates the number of new spacers (shown at the top of
the gel). Cells without additional spacers resist infection by a CRISPRindependent mechanism, presumably envelope resistance. (b) Analysis of
acquired spacers during phage infection of a population of bacteria carrying the
S. pyogenes type II CRISPR–Cas system. Liquid cultures of bacteria were
infected with phage, surviving cells were collected at the end of the infection,
DNA extracted and used as template for a PCR reaction as described above.
Amplification products were separated by agarose gel electrophoresis and the
DNA of the bands corresponding to products with additional spacers was
extracted and sent for MiSeq next generation sequencing. Reads corresponding
to newly acquired spacers were plotted according to their position in the phage
genome (x axis) and their abundance (y axis). Each dot represents a unique
spacer sequence; blue and red dots indicate a corresponding protospacer with
an NGG or non-NGG PAM. Top and bottom plots indicate protospacers in the top
and bottom strands of the viral DNA. The map as well as the different functions of
the phage genes are indicated in between the plots. (c) Weblogo showing the
conservation of the 59 flanking sequences of 10,000 protospacers randomly
selected from the experiment shown in b. Absolute conservation of the NGG
PAM was observed.
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Figure 2-3. Cas1, cas2 and csn2 are not required for the execution
of immunity. (a) Analysis of bacteriophage-resistant mutants that do not
acquire a new spacer. Three colonies that survived phage infection in our in-plate
adaptation assay (Figure 2-2) were subjected to phage adsorption assay. Briefly,
surviving colonies as well as the wild-type S. aureus RN4220 control were grown
in liquid and mixed with bacteriophage. After a brief incubation, cells were
pelleted by centrifugation and the phages present in the supernatant (unable to
bind and infect cells) were counted on a lawn of sensitive cells. The number of
plaque-forming units (p.f.u.) of a control experiment in the absence of host cells
were used to determine the 100% free phage, or 0% adsorption value. No
plaques were observed in the control experiment using wild-type cells and this
value was used to set the 100% adsorption limit. The three CRISPRindependent, bacteriophage-resistant mutants displayed a marked defect in
phage adsorption (about 50%), indicating that most likely they carry envelope
resistance mutations. (b) cas1, cas2 and csn2 are not required for the execution
of immunity using previously acquired spacers. Position within the phage NM4
genome of the type II CRISPR–Cas target used in this experiment. The
protospacer sequence is in the bottom strand (shown in 3’–5’ direction) and
flanked by a TGG PAM (in green). (c) Comparison of immunity provided by a
type II CRISPR–Cas system programmed to target the sequence shown in panel
(a) in the presence (wild-type, wt) or absence (dcas1,dcas2, dcsn2) of cas1,
cas2 and csn2. Immunity is measured as the p.f.u. of a phage lysate spotted on
top agar lawns of S. aureus RN4220 cells containing no CRISPR system, a wildtype S. pyogenes CRISPR–Cas type II system (wt, pRH233), or the same
CRISPR–Cas systems with a deletion of cas1, cas2 and csn2 genes (dcas1,
dcas2, dcsn2, pRH079).
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To determine whether these genes are also sufficient for this process,
Iover-expressed cas1, cas2 and csn2 in the absence of cas9 using a
tetracycline-inducible promoter in plasmid pRH223 and looked for the integration
of new spacers in the absence of phage infection using a highly sensitive PCR
assay (Figure 2-4). Iwere unable to detect new spacers even in the presence of
the inducer (Fig. 2-1c). However, the addition of a second plasmid expressing
tracrRNA and Cas9 from their native promoters (Figure 2-4a) enabled spacer
acquisition only in the presence of the inducer, with all the new spacers matching
chromosomal or plasmid sequences (Figure 2-1c). Although most likely the
acquisition of such spacers causes cell death or plasmid curing, respectively, the
acquisition event can still be detected in liquid culture using our highly sensitive
PCR assay (Figure 2-4b and c). The tracRNA (Figure 2-1a) is a small RNA
bound by Cas9 that is required for crRNA processing and Cas9 nuclease activity.
Iwondered if Cas9 involvement in spacer acquisition also required the presence
of the tracrRNA. Deletion of the tracrRNA prevented spacer acquisition in the
absence of phage infection (Figure 2-1c), suggesting that apo-Cas9 is not
sufficient to promote spacer acquisition and that association with its cofactor is
also required. Altogether these data indicate that Cas1, Cas2 and Csn2 are
necessary but not sufficient for the incorporation of new spacers and that
tracrRNA/Cas9 is also required. This is in contrast to the type I-E CRISPR-Cas
system of E. coli, where over-expression of Cas1 and Cas2 alone is sufficient for
spacer acquisition. It is important to note that the CRISPR array used in this
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assay consists of a single repeat, without pre-existing spacers (Figure 2-4).
Therefore, the Cas9 requirement is not a consequence of the phenomenon
known as “primed” spacer acquisition. This refers to an increase in the frequency
of spacer acquisition observed in type I CRISPR-Cas systems that relies on the
presence of a pre-existing spacer with a partial match to the phage genome as
well as the full targeting complex (Cascade)26,31,74.
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Figure

2-4.

Generation

of

an

experimental

system

for

the

overexpression of cas1, cas2 and csn2 and the detection of spacer
acquisition in the absence of phage infection. (a) Plasmids used in the
spacer acquisition experiments presented in Figure 2-1c and 2-6c and d. pRH223
contains cas1, cas2 and csn2 from S. pyogenes under a tetracycline-inducible
promoter. Cells containing this plasmid only acquired spacers when a second
plasmid expressing cas9 was introduced, pRH240 or pRH241, containing the
tracrRNA gene, the leader and first repeat from the S. pyogenes type II CRISPR–
Cas system as well as cas9 from S. pyogenes (cas9Sp) or S. thermophilus
(cas9St), respectively. The leader is a short, AT-rich sequence immediately
upstream of the first repeat that contains the promoter for the transcription of the
CRISPR array. (b) Highly sensitive PCR assay to enrich for amplification
products of adapted CRISPR loci. Arrows indicate primer annealing position and
direction. The forward primer (JW8) anneals on the leader. For the reverse
primer, a cocktail of JW3, JW4 and JW5 was used. The three reverse primers
anneal on the repeat and differ only in their 3’-end nucleotide that never matches
the last nucleotide of the leader (red arrowhead). Because this nucleotide is
critical for the annealing of the primers, loci that acquire spacers ending in A, C or
T are preferentially amplified over unadapted loci. (c) To quantify the sensitivity
of this technique, Imixed pGG32 (one repeat, unadapted) with pRH087 (repeatspacer-repeat, adapted) in known ratios. The amplification of adapted plasmid
was detected even when it represented 0.01% of the total plasmid template,
representative of three technical replicates. This highly sensitive PCR assay is
not required to detect acquisition during phage infection, as in this case adapted
cells survive and are enriched within the population, making their detection much
easier.
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2.3. Cas9 specifies the PAM sequence of newly acquired spacers
Given this newfound requirement in the CRISPR adaptation process and
the well-established PAM recognition function of Cas9 during the surveillance
and destruction of viral target sequences, I hypothesized that this nuclease could
participate in the selection of PAM sequences during spacer acquisition. To test
this I exchanged the cas9 genes of S. pyogenes (Sp) and S. thermophilus (St)
CRISPR-Cas systems to create two chimeric CRISPR loci: tracrRNASp-cas9Stcas1Sp-cas2Sp-csn2Sp and tracrRNASt-cas9Sp-cas1St-cas2St-csn2St (Figure 2-6a). I
chose the type II-A CRISPR-Cas system of S. thermophilus (also known as
CRISPR3) because it is an ortholog of the S. pyogenes system75. While the PAM
sequence for the Sp CRISPR-Cas system is NGG, the PAM sequence for the St
system is NGGNG16 (Figure 2-6b). I infected each naïve strain with phage
ϕNM4γ4, sequenced the newly acquired spacers, and obtained the PAM of the
matching protospacers using WebLogo76. I found that each chimeric system
acquired spacers with PAMs that correlated with the cas9, but not the tracrRNA,
cas1, cas2 or csn2, allele present (Figure 2-6b). To rule out the possibility that
non-functional spacers are negatively selected during phage infection, i.e. they
are acquired randomly and only those cells containing spacers with a correct
PAM for Cas9 cleavage provide immunity and allow cell survival, I sequenced the
PAMs of spacers acquired in the absence of phage infection (Fig. 2-1c and 2-6c).
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Either Cas9Sp or Cas9St were produced in cells overexpressing Cas1Sp, Cas2Sp
and Csn2Sp. In this experiment, as explained above, spacers matching
chromosomal or plasmid sequences will be acquired. The PCR products
containing new spacers were cloned into a commercial vector from which they
were sequenced. Expression of Cas9Sp led to the incorporation of spacers
matching protospacers with an NGG PAM sequence, whereas the expression of
Cas9St in the same cells shifted the composition of the PAM to NGGNG (Fig. 26d). These results demonstrate that Cas9 specifies PAM sequences to ensure
the acquisition of functional spacers during CRISPR adaptation.

Figure

2-6.

Cas9

determines

the

PAM

sequence

of

acquired

spacers. (a) (c) Genetic composition of the CRISPR–Cas loci tested for spacer
during phage infection (a), or in the absence of infection (c), with the
experimental set up shown in Figure 2-4. (b) (d) Sequence logos obtained after
the alignment of the 3’ flanking sequences of the protospacers matched by the
newly acquired spacers in panels (a) and (c) respectively. Numbers indicate the
positions of the flanking nucleotides downstream from the spacer. Number of
sequences used in each alignment indicated as n.
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2.4. Cas9 associates with other Cas proteins involved in spacer
acquisition
In type I CRISPR-Cas systems, Cas1 and Cas2 form a complex70 and the
dsDNA nuclease activity of Cas1 has been implicated in the initial cleavage of the
invading viral DNA to generate a new spacer48. The genetic analyses presented
above suggest that in the type II S. pyogenes CRISPR-Cas system, the PAMbinding function of Cas9 observed in vitro67 could specify a PAM-adjacent site of
cleavage for Cas1, or other members of the spacer acquisition machinery. This
would guarantee that newly acquired spacers have the correct PAM needed for
Cas9 activity later in this immune pathway. This hypothesis predicts an
interaction between Cas9 and Cas1, Cas2 and/or Csn2. To test this, I expressed
the type II Cas operon in E. coli, using a histidyl tagged version of Cas9, and
looked for other proteins that co-purify. I observed an abundant co-purifying
protein with an apparent molecular weight close to 33 kDa, the expected size of
Cas1 (Figure 2-5).
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Figure 2-5. Purification of a Cas9–Cas1–Cas2–Csn2 complexes. (a)

The cas9–cas1–cas2–csn2 operon of S. pyogenes SF370 was cloned into the
pET16b vector (generating pKW07) to add an N-terminal histidyl tag to Cas9 and
express all proteins in E. coli. Purification was performed using Ni-NTA affinity
chromatography. SDS–PAGE followed by Coomassie staining of the purified
proteins revealed a co-purifying protein that was identified as Cas1 by mass
spectrometry, in a result representative of five technical replicates. (b) The cas9–
cas1– cas2–csn2 operon of S. pyogenes SF370 was cloned into the pET23a
vector (generating pKW06) to add a C-terminal histidyl tag to Csn2 and express
all proteins in E. coli. Purification was performed using Ni-NTA affinity
chromatography followed by ion exchange chromatography. The elution fractions
that constituted the peak containing the complex (Figure 2-7a) were separated by
SDS–PAGE and visualized

Mass spectrometry confirmed the identity of both of these proteins as well
as the presence of Cas2 and Csn2 co-purifying with Cas9 (Table 1). This result
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suggested the formation of a Cas9-Cas1-Cas2-Csn2 complex and therefore I
explored other purification strategies to unequivocally determine its existence. I
was able to isolate a Cas9-Cas1-Cas2-Csn2 complex when the histidyl tag was
added to Csn2 (Figure 2-7a and b). The identity of the purified proteins was
confirmed by mass spectrometry (Table 2). This demonstrates a biochemical link
between the Cas9 nuclease and the other Cas proteins that function exclusively
to acquire new spacers, supporting the role of Cas9 as a PAM specificity factor in
the adaptation phase of CRISPR immunity.

Table 1. Mass spectrometry analysis of proteins purified through NiNTA
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Table 2. Mass spectrometry analysis of protein bands from the
purified Cas9–Cas1–Cas2–Csn2 complex
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Figure 2-7. S. pyogenes Cas9 PAM recognition domain is required
for the acquisition of spacers with an NGG PAM sequence. (a)
Separation

of

the

Cas9–Cas1–Cas2–Csn2

complex

by

ion

exchange

chromatography. (b) SDS– PAGE of fraction 19 (peak) from the complex elution
shown in panel (a), representative of five technical replicates. The four proteins of
the complex were individually purified and run alongside the purified fraction to
identify each protein in the complex. (c) Spacer acquisition was tested as in
Figure 2-1c in the presence or absence of different Cas1 or Cas9 activities.
Image is representative of eight technical replicates. dCas1, nuclease-dead Cas1
(E220A mutation); dCas9, nuclease-dead Cas9 (D10A, H840A mutations);
Cas9PAM lacks the PAM recognition function (R1333Q, R1335Q mutations). (d)
Sequence logos obtained after the alignment of the 39 flanking sequences of the
protospacers matched by the newly acquired spacers in panel (c). Numbers
indicate the positions of the flanking nucleotides downstream from the spacer.
Number of sequences used in each alignment indicated as n.
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2.5. The PAM binding motif of Cas9 is required for PAM selection
Within this complex the PAM-binding domain of Cas9 would specify a
functional spacer (one adjacent to a correct PAM) and the nuclease activity of
Cas1 and/or Cas9 would cleave the invading DNA to extract the spacer
sequence. To test this I performed adaptation studies in the absence of phage
selection as described in Figure 2-4 but using different combinations of wild-type
Cas1, Cas1E220A (catalytically dead or dCas148), wild-type Cas9, Cas9D10A,H840A
(catalytically dead or dCas934) and Cas9R1333Q,R1335Q (Cas9PAM, containing
mutations in the PAM-binding motif that substantially reduces binding to target
DNA sequences with NGG PAMs in vitro71). I observed that the nuclease activity
of Cas1 is necessary for spacer acquisition (Figure 2-7c). In contrast, the
nuclease activity and PAM-binding function of Cas9 are dispensable for this
process. Next I determined the PAM of the acquired spacers in the presence of
mutated Cas9 (Figure 2-7). I found that whereas spacers acquired in the
presence of dCas9 displayed correct PAMs, those acquired in the presence of
Cas9PAM matched DNA regions without a conserved flanking sequence, i.e.
without a PAM sequence. The same result was obtained with St dCas9 (Figure 28). Altogether these results indicate that Cas1 and Cas9 are part of a complex
dedicated to spacer acquisition which requires Cas1 nuclease activity and Cas9
PAM-binding properties for the selection of new spacer sequences.
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Figure 2-8. dCas9 St can also support spacer acquisition. A plasmid
derived from pRH241 containing mutations in the active site of S. thermophilus
Cas9 (D10A, H847A; dCas9St) was used to characterize spacer acquisition in
the absence of phage infection. Upon overexpression of Cas1, Cas2 and Csn2
using anydrotetracycline (aTc), I was able to detect spacer acquisition.
Sequencing of spacers and alignment of the protospacer flanking sequences
demonstrated the selection of an NGGNG PAM. The image is representative of
three technical replicates.
2.6. Discussion
The selection of new spacers with a correct PAM is fundamental for the
survival of the infected host during CRISPR-Cas immunity. In the simplest
scenario there is no active selection of PAM-flanked protospacers; any spacer
sequence can be acquired but only those with the correct PAM allow Cas9
cleavage of the invader and survival. Bacteria that acquire spacers with
ineffective flanking sequences are killed by the virus and as a consequence
PAM-flanking spacers are enriched in the population. Here I show that even in
the absence of phage selection, the type II CRISPR-Cas system acquires new
spacers with correct PAMs, a result that rules out the possibility of random
spacer selection with subsequent selection for functional spacers. How are PAMflanked protospacers selected during type II CRISPR-Cas immunity? One

41

possibility is that the proteins exclusively dedicated to spacer acquisition perform
the PAM-selection function. The inability of cells over-expressing only cas1, cas2
and csn2 to expand the CRISPR array strongly suggest that none of the proteins
encoded by these genes can recognize and select correct PAMs. Another
possibility is that the known PAM recognition function of Cas971,77, essential for
destroying the invading virus, could also be used during spacer acquisition to
recognize PAM-flanking viral sequences. Experiments showing that the cas9
allele, but not the cas1-cas2-csn2 alleles, determine the PAM sequence of the
newly acquired spacers, demonstrated that this scenario is likely correct. How
does Cas9 select new spacers with the correct PAMs? Our experiments
demonstrate that Cas9 forms a stable complex with Cas1, Cas2 and Csn2 that
presumably participates in the selection of new spacers.
The nuclease activity of Cas1, but not of Cas9, is required for spacer
acquisition. The tracrRNA is also required, suggesting that the apo-Cas9
structure77, very different from holo-Cas971, does not have the correct
conformation to participate in spacer acquisition. The key residues involved in
Cas9 PAM recognition are not required for spacer acquisition, but they are
necessary for the incorporation of new spacers with the correct PAM sequence.
This suggests that the reported non-specific DNA binding property of Cas934,67 is
sufficient for spacer acquisition, but not for the selection of functional spacers.
There are currently two models for the incorporation of new spacers into the
CRISPR array, one where the future spacer sequence is cut from the invading
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viral DNA, the “cut and paste” model, and another where this sequence is copied
from the viral genome, the “copy and paste” model78. In the context of the first
model, our data suggests that, at a low frequency that may reflect the dynamics
of spacer acquisition, Cas1 cleaves the invading genome to extract a new spacer
sequence. However, on its own, Cas1 nuclease activity is non-specific48.
Therefore, I propose that through the formation of the Cas9-Cas1-Cas2-Csn2
complex, Cas9 binding to PAM-adjacent sequences provides specificity to Cas1
endonuclease activity. In the “copy and paste” model, Cas1 nuclease activity is
most likely necessary for downstream events, such as the cleavage of the repeat
sequence that precedes spacer insertion, and Cas9 is required to “mark”
sequences adjacent to GG motifs to be copied into the CRISPR array. In any
case, following yet unknown processing and integration events, the selected DNA
becomes a new functional spacer, i.e. its matching protospacer will have the
correct PAM to license Cas9 cleavage (Figure 2-9). The molecular steps that
take place after protospacer selection to incorporate it as a new spacer in the
CRISPR array are still unknown. All genes of the type II-A CRISPR-Cas locus
(tracrRNA, cas9, cas1, cas2 and csn2) are required for spacer acquisition,
therefore most likely all the members of the Cas9-Cas1-Cas2-Csn2 complex
participate in the process. Future work will address this and other aspects of the
mechanisms of spacer integration in different CRISPR-Cas systems.
The present chapter reveals a new function for Cas9 in CRISPR immunity.
This nuclease is fundamental for both the execution of immunity, participating in
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the surveillance and destruction of infectious target viruses, and the generation of
immunological memory, selecting the viral sequences that allow adaptation and
resistance to viral predators.

Figure 2-9. A model for the selection of PAM-flanking spacers by
Cas9. After injection of the phage DNA, an adaptation complex formed by Cas9,
Cas1, Cas2 and Csn2 uses the Cas9 PAM binding domain to specify functional
protospacers, that is, that are followed by the correct PAM. It is not known how
the protospacer sequence is extracted from the viral DNA to become a spacer. In
the ‘cut and paste’ model, a nuclease, possibly Cas1, cuts the viral DNA to
generate the spacer. In the ‘copy and paste’ model the protospacer sequence is
copied first. Once loaded with the selected protospacer sequence, this complex
promotes the integration of this sequence into the CRISPR array, thus becoming
a new spacer. Previous studies demonstrated that Cas1 dimerizes and interacts
with Cas270, Csn2 has been determined to forma tetramer63.
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Chapter III.
Generation

of

Cas9

Variants

that

Increase Spacer Acquisition

Having learned that Cas9 participates in spacer acquisition by specifying
functional viral targets, I wanted to further explore this topic by engineering Cas9
mutants that provide enhanced CRISPR immunity. Here I performed random
mutagenesis of the RNA-guided Cas9 nuclease to look for variants that provide
enhanced immunity against viral infection. I identified a mutation, I473F, which
increases the rate of spacer acquisition by more than two orders of magnitude.
The results presented in this chapter highlight the role of Cas9 during CRISPR
immunization and provide a useful tool to study this otherwise rare process and
develop it as a biotechnological application.

3.1 Changing the PAM specificity of Cas9
Based on their cas genetic repertoire, CRISPR-Cas systems have been
classified into six types, I through VI24,83. Cas9 is the crRNA-guided nuclease of
the type II-A CRISPR-Cas system of Streptococcus pyogenes34. In addition to
protospacer recognition by the crRNA, Cas9 target cleavage requires a 5’-NGG-
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3’

protospacer

adjacent

motif

(PAM)

immediately

downstream

of

the

target17,33,34,71. Cas9 is also required for the immunization step of the CRISPR
response84,85, using its PAM binding domain to specify functional spacer
sequences that are flanked by the required NGG motif84. In support of its role in
spacer acquisition, Cas9 can associate in vivo with the other proteins encoded by
the type II-A CRISPR-Cas system: Cas1, Cas2 and Csn284.
To further study the role of Cas9 in spacer acquisition, I decided to change
its PAM specificity. Earlier work from our lab tested in vivo cleavage of targets
having the same protospacer sequence but different PAMs displaying all possible
trinucleotide combinations. I found that, in addition to the complete cleavage of
targets with NGG PAMs, wild-type Cas9 displays approximately 50% of in vivo
cleavage of targets with NAG PAMs. In an effort to understand how Cas9 affects
the acquisition of spacers flanked by NGG motifs, I decided to evolve this weak
but detectable affinity of the nuclease for NAG PAMs. After structural analysis
determined the PAM interacting domain of Cas971,77, different groups have
specifically mutated this domain to obtain a versatile set of nucleases for genome
editing purposes and have obtained an NAG-recognizing Cas986. I took a
different approach and searched for mutations in any region of the nuclease that
would increase its specificity for NAG-flanked targets. I found one such mutation,
I473F, which provided partial immunity when directed (programmed) to recognize
an NAG viral protospacer. Importantly, this mutation also expanded the levels of
the CRISPR-Cas adaptive immune response, increasing the number of CRISPR-
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mediated, bacteriophage-resistant colonies by more than two orders of
magnitude. I performed experiments to understand the molecular basis of the
enhanced CRISPR-Cas immunity and determined that the I473F mutation
mediates a significant increase in spacer acquisition. Our results highlight the
role of Cas9 during CRISPR immunization and provide a useful tool to study this
otherwise rare process.
3.2. Evolved Cas9 has increased NAG PAM specificity

S. pyogenes Cas9 has an innate ability to cleave NAG-adjacent targets,
but with much lower efficiency than it cleaves canonical (NGG) targets33. To
enhance the ability of the nuclease to target protospacer sequences flanked by
NAG PAMs, I constructed a library of plasmids carrying mutagenized cas9
variants by subjecting the entire gene to error-prone PCR (Figure 3 -1a). The
library plasmids also harbor the trans-activating crRNA (tracrRNA) gene44 and a
single-spacer

CRISPR

array

targeting

a

protospacer

sequence

(AAAAACAAAAATGTTTTAACACCTATTAACG) followed by a TAG PAM on the
genome of the lytic staphylococcal bacteriophage ϕNM4γ464. The library was
transformed into Staphylococcus aureus RN4220 cells that were subjected to
phage infection on soft-agar plates to select for phage-resistant bacterial
colonies. These colonies originated either from cells that acquired surface
mutations preventing phage adsorption or cells harboring mutant cas9 alleles
with improved NAG cleaving efficiency that can sustain anti-viral immunity. To
enrich for bacteria harboring desired Cas9 mutants, I isolated and re-transformed
the plasmids of surviving colonies to perform a second round of phage infection.
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Several colonies were obtained, and I proceeded with a further analysis of one of
the “evolved” mutants that gained phage resistance. Sequencing of the plasmid
revealed the presence of six single-nucleotide substitutions in the cas9 gene,
producing the following missense mutations: R425G, I473F, K500I, S701G,
P756L and A1032G.
To evaluate the importance of each of these mutations in the gain-offunction phenotype I introduced them individually into the cas9 gene and tested
the ability of the resulting plasmid to prevent ϕNM4γ4 propagation by measuring
the number of plaque forming units (pfu) that result after infection of the host cells
(Figure 3-1b). Whereas cells harboring a control vector do not provide any
immunity and allow high levels of phage propagation (up to ~1010 pfu/ml), cells
containing wild-type Cas9 provide partial immunity and reduce phage
propagation by about two orders of magnitude. Cas9 harboring the R425G,
S701G, P756L and A1032G mutations allow wild-type levels of phage
propagation and therefore do not contribute to the gain-of-function-phenotype of
the evolved cas9 allele I isolated. In contrast, cells containing Cas9 with the
I473F or K500I mutations decrease phage propagation by about four orders of
magnitude. This is close to the levels of immunity provided by wild-type Cas9
when programmed against NGG-flanked targets (a reduction of ~ 5 orders of
magnitude, see Figure 3-3b). Similar results were obtained when other NAG
PAMs were used in this assay (AAG, CAG, GAG, Fig. S1). Therefore, the I473F
and K500I mutations enhance the ability of Cas9 to recognize targets with NAG
flanking PAMs.
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Figure 3-1. Directed Evolution of cas9 Generates Mutants with
Increased Specificity for NAG Targets (a) Schematic diagram of the
directed evolution assay. S. pyogenes cas9 was mutagenized by error-prone
PCR and library amplicons were cloned into a plasmid carrying a spacer
matching a TAG- adjacent target sequence on the fNM4g4 phage. Library cells
were infected with lytic phage to screen for mutants displaying improved NAG
cleaving efficiency. (b) Phage propagation was measured as the number of
plaque-forming units (PFUs) per milliliter of stock on cells targeting the NAGadjacent proto- spacer and harboring plasmids with different mutations on cas9:
one of the ‘‘evolved’’ alleles or each of the six mutations present in this allele.
Mutations with PFU values significantly different than wild- type are highlighted
(**p < 0.05 compared to WTCas9). Data are represented as mean ± SD of three
representative biological replicates. (c) Colony-forming units (CFUs) obtained
after phage infection of naive cells (not programmed to target any viral sequence)
harboring plasmids with different mutations in cas9. Mutations with CFU values
significantly different than wild-type are highlighted. Data are represented as
mean ± SD of three representative biological replicates. (d) Location of residues
I473 and K500 on the Cas9:single-guide RNA ribonucleoprotein (PDB: 4UN3).
Red, I473; purple, K500; orange, sgRNA; green, target DNA (the GG PAM
highlighted in red); gray, a-helical (REC) lobe; yellow, HNH domain; light blue,
RuvC domain; blue, PAM-interacting CTD.
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Figure 3-2. Protection of host cells by hCas9 programmed against
different

NAG-flanked

targets. (a) The ability of hCas9 to target

protospacers with different PAM was tested by measuring phage propagation in
cells harboring CRISPR-Cas systems containing either wtCas9 or hCas9 and
programmed to target the sequences shown, which are followed by TAG, AAG,
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GAG or CAG PAMs. (b) Phage propagation was measured as the number of
plaque forming units (pfu) per ml of stock, on cells targeting the TAG, AAG, GAG,
and CAG-adjacent protospacers and hCas9. Data are represented as mean ± SD
of three representative biological replicates. (c) Measurement of pfu formation on
staphylococci carrying plasmids with different cas9 mutations after infection with
φ85, a phage lacking the target recognized in φNM4γ4. Data are represented as
mean ± SD of three representative biological replicates. (d) Location of residue
K500 on the Cas9:single-guide RNA ribonucleoprotein (PDB 4UN3). Purple,
K500; orange, sgRNA; green, target DNA (the GG PAM highlighted in red); grey,
alpha-helical (REC) lobe; yellow, HNH domain; light blue, RuvC domain; blue,
PAM-interacting CTD.

Given the requirement of Cas9 for the immunization phase of the CRISPRCas immune response, i.e. the generation of phage-resistant bacteria through the
acquisition of viral sequences as spacers84,85, I wondered whether the evolved
Cas9 as well as the individual mutants affected this process. To test this, I
introduced the different alleles of cas9 into a plasmid also harboring the tracrRNA
coding sequence, the S. pyogenes SF370 CRISPR array (containing six spacers,
none of them matching the genome of ϕNM4γ4) and the type II-A genes involved
exclusively in the acquisition of new spacers, cas1, cas2 and csn284,85. S. aureus
cells containing the different plasmids were infected with ϕNM4γ4 and the
number of survivors were enumerated as colony forming units (cfu) (Figure 3-1c).
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Cells harboring a vector control provide the threshold for the number of nonCRISPR phage resistant mutants. Only a small fraction of cells containing wildtype Cas9 are able to acquire new spacers, about 2-fold over the threshold
control. In contrast, the evolved cas9 allele containing all six mutations increased
the number of CRISPR-surviving cells by about 60-fold. Analysis of single
mutants revealed that this highly significant increase was provided almost
exclusively by the I473F mutation (Figure 3-1c). Due to the sharp enhancement
of the CRISPR-Cas immune response conferred by the I473F mutation I decided
to name the Cas9I437F mutant “hyper-Cas9”, or hCas9. I473 is located close to
the surface of Cas9, outside of the PAM-interacting domain, and it is part of a
projection from the Helical III domain that interacts with the nexus of the guide
RNA87 (Figure 3-1d). This position does not suggest an evident effect of the
I473F mutation on Cas9 activity and therefore I decided to investigate the basis
for its phenotype by performing a detailed comparison with the CRISPR-Cas
immune response mediated by wild-type Cas9.

3.3. Mutant Cas9 enhances CRISPR adaptive immunity by 100-fold
To perform a more accurate comparison between wild-type (wtCas9) and
hCas9, I counted the number of CRISPR-mediated, phage resistant cells that
arise after phage infection. Figure 3-3a shows representative plates of infected
cells containing plasmids with the wtCas9 or hCas9 S. pyogenes CRISPR-Cas
locus, showing a striking difference in the number of surviving colonies. As

53

mentioned before, most of these colonies arise from single cells that were able to
acquire a new spacer matching the ϕNM4γ4 genome. However, a fraction of the
surviving cells repels phage attack by non-CRISPR related mechanisms, such as
envelope resistance84. To make a more accurate quantification of the CRISPRCas response, I analyzed individual colonies by PCR of the CRISPR array28,84 to
detect those in which new spacers were acquired, i.e. “adapted” cells (Figure 33b). Not only did many more resistant colonies originated from cells harboring
hCas9 (an average of 31 cfu for wtCas9 vs 4,312 cfu for hCas9, Figure 3-3c), but
also most of them showed CRISPR-mediated phage resistance (23% for wtCas9
vs 90% for hCas9, Figure 3-3c).

We wondered whether this was a consequence of the specific substitution
of I473 by phenylalanine. To test this, I introduced an I473A mutation into Cas9
and compared this mutant with wtCas9 and hCas9 in this assay (Figure 3-4). I
found that cells harboring the I473A mutant produced a number of CRISPRmediated immune cfu comparable to cells carrying wtCas9, but 10 times lower
than the cfu obtained from infection of cells expressing hCas9. Therefore, I
conclude that the I473F mutation increases the CRISPR-adaptive immune
response through a specific effect of the phenylalanine residue in position 473
and by more than two orders of magnitude: on average, approximately 7 cfu
(31×0.23) per experiment for infected wtCas9-containing cells, and approximately
3,863 cfu (4,312×0.90) for infected hCas9-expressing bacteria. I sequenced PCR
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Figure 3-3. Cas9 I473F or hyper-Cas9 Mounts an Enhanced CRISPR
Adaptive Immune Response. (a) Representative plates obtained after lytic
infection of cells harboring the full CRISPR system of S. pyogenes with WTCas9
or hyperCas9 (hCas9) showing the number of surviving colonies. (b) Agarose
gel electrophoresis of PCR products of the amplification of the CRISPR of arrays
of surviving cells to detect newly acquired spacers (asterisks). Molecular markers
(in kilobases) are indicated in black and the number of new spacers added in
green. (c) Quantification of total surviving colonies (gray bars) and surviving
colonies with newly incorporated spacers, as detected by PCR (blue and red
bars). Data are represented as mean ± SD of three representative biological
replicates. (d) Growth curves of cultures of cells harboring the full CRISPR
system of S. pyogenes with WTCas9 or hCas9 with (+) or without (-) phage
infection. (e) PCR-based analysis of the liquid cultures shown in (c) (at 24 hr
post-infection) to check for the acquisition of new spacer sequences in the
presence (+) or the absence (-) of phage infection by cells expressing WTCas9
or hCas9. Molecular markers (in kilobases) are indicated in black and the number
of new spacers added in green. Image is representative of three technical
replicates.
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products to determine the PAM of the spacers acquired by 40 colonies
expressing wtCas9 or hCas9. Interestingly, all 40 spacers acquired by cells
expressing hCas9 matched targets with an NGG PAM, suggesting that this
nuclease can still target sequences followed by the canonical PAM in addition to
targets with NAG PAMs.

Figure 3-4. CRISPR-Cas immune response of cells expressing
Cas9 I473A . Cultures harboring plasmids with tracrRNA, cas1, cas2 and csn2
genes, and either wild-type, I473F or I473A cas9 alleles, were infected with
ΦNM4γ4 phage on top agar media and poured on plates. After 24 hours of
incubation at 37 °C the CRISPR-surviving colonies were counted. Data are
represented as mean ± SD of three representative biological replicates.
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Similar results were observed when cells in culture carrying naïve wtCas9
or hCas9 CRISPR-Cas systems were infected with phage. Upon addition of
ϕNM4γ4, the cultures lyse, as the vast majority of cells do not undergo spacer
acquisition (Figure 3-3). Nonetheless, hCas9 cultures were able to regrow much
earlier (~14 hours post-infection) than wtCas9 cultures (~17 hours post-infection).
PCR analysis of the population of surviving cells (i.e., using DNA extracted from
the whole culture, not individual resistant bacteria) at 24 hours post-infection
corroborated the earlier observation that hCas9 cells mount a more robust
CRISPR immune response (Figure 3-3e). Whereas the PCR products using DNA
from immune cells carrying wtCas9 showed the presence of both adapted and
non-adapted CRISPR arrays in the surviving population, the PCR results from
cultures carrying hCas9 showed very little non-adapted CRISPR arrays, with the
great majority of the cells acquiring one or two new spacers. Altogether these
data show that the I473F mutation in Cas9 allows for a more robust CRISPR-Cas
immune response due to a specific effect of the phenylalanine residue.
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3.3.1.

Hyper Cas9 provides wild-type cleavage efficiency
The CRISPR-Cas response can be divided into two distinct stages7. First

there is spacer acquisition, where sequences from the invading virus are
incorporated into the CRISPR array. This is followed by the second stage where
the acquired spacers provide the crRNA guides to the Cas nucleases for the
destruction of the viral DNA. Therefore, the enhanced immunity phenotype of
hCas9 documented in Figure 3-3 could be in principle due to an increase in the
frequency of spacer acquisition, a more robust cleavage by hCas9 of its targets,
or both.
First, I considered the possibility that hCas9 could provide better cleavage
of the infecting viral DNA. In this scenario both wtCas9 and hCas9 populations
can acquire a similar number of new spacers but a more robust cleavage of the
target DNA by hCas9 would lead to a faster recovery of the bacteria that acquired
the spacers. This will result in the clonal expansion and the consequent increase
in the number of surviving bacteria. To test this hypothesis, I infected cells
carrying plasmids with either wtCas9 or hCas9 programmed to target the
ϕNM4γ4 virus and the tracrRNA gene, but without the spacer acquisition
machinery (cas1, cas2 and csn2). This genetic background supports CRISPRCas anti-viral defense but does not allow the acquisition of new spacer
sequences84. Because our data suggested that hCas9 can still target
protospacers followed by NGG PAMs, I tested the immunity of cells programmed
to attack targets with either an NAG or an NGG PAM located in the same region
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of the ϕNM4γ4 genome (Figure 3-5). As a control, cells harboring a vector
control were also infected.

Figure 3-5. In vivo and in vitro targets. (a) Region of the ΦNM4γ4 phage
genome (nucleotides 1441 to 1490) containing the TAG- and TGG-flanked
protospacers, yellow and blue respectively, used in Figures 3-6a and 3-6b.(b)
Sequences of the dsDNA target oligonucleotides used in Figure 3-6c. The
protospacer sequence is the same, but it is flanked by either a TAG (yellow) or
TGG (blue) PAM sequence. Radiolabel is at the 5’ end (P). Grey and black
arrowheads mark the cleavage sites of the RuvC and HNH domains,
respectively.

Bacteria containing different plasmids were infected with phage during
exponential growth and the optical density of the culture was followed over time
to measure the immunity provided by Cas9 cleavage of the viral genome (Figure
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3-6a). As expected, control cells were rapidly lysed by the addition of phage. In
contrast, cells expressing wtCas9 programmed against an NGG target cleared
the infection efficiently and continued the exponential growth. In contrast, the
poor targeting of NAG-flanked protospacers by wtCas9 led to substantial lysis,
although not as dramatic as the non-Cas9 control, suggesting a low level of
target cleavage. The population of hCas9-containing cells targeting an NGGflanked viral protospacer was protected to levels indistinguishable from the
immunity provided by bacteria expressing wtCas9 programmed against the same
target. Targeting of the protospacer followed by an NAG PAM was more efficient
in cells having hCas9 than in the wtCas9 population. However, hCas9 did not
provide full immunity as was the case for NGG-containing targets. Similar results
were obtained when phage propagation was measured instead of cell survival
(Figure 3-6b). To do this, I compared the number of plaques (measured as
plaque forming units or pfu) obtained when a ϕNM4γ4 lysate was applied to
plates seeded with the five different cultures used in Figure 3-6a. Cells harboring
an empty vector allowed extensive phage propagation, up to more than 1010 pfu
per ml of phage stock. In contrast, bacteria harboring wtCas9 or hCas9
programmed to target the NGG-flanked protospacer in the ϕNM4γ4 genome
reduced phage proliferation by more than four orders of magnitude (~ 106 pfu/ml).
When the target contained an NAG PAM, wtCas9 only reduced viral
multiplication by an order of magnitude compared to the non-CRISPR control,
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whereas hCas9 reduced it by about three orders of magnitude, but nevertheless
failing to fully restrict the virus.

Figure 3-6. hCas9 has increased interference efficiency against
NAG-adjacent, but Not NGG-adjacent, targets. (a) Growth curves of
cultures infected with fNM4g4 harboring the WTCas9 or hCas9 (but not Cas1,
Cas2, and Csn2) programmed to target either NAG- or NGG-flanked viral
sequences. (b) Phage propagation, measured in PFU/mL, of the bacteria
presented in (a). Data are represented as mean ± SD of three representative
biological replicates. (c) Cleavage of radiolabeled dsDNA targets, flanked by
either NGG or NAG PAMs, by WTCas9 or hCas9. (d) Quantification of the
cleavage results shown in (c). Data are represented as mean ± SD of three
representative biological replicates.
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Both in vivo experiments measuring bacterial survival (Figure 3-6a) and
phage propagation (Figure 3-6b) suggest that hCas9 has not improved efficiency
of cleavage of NGG-flanked targets and displays only a small increase in the
cleavage of NAG-flanked sequences. To unequivocally demonstrate this, I
performed in vitro cleavage assays with purified wtCas9 and hCas9 (Figure 36c). In this case,

I was able to compare cleavage of radiolabeled

oligonucleotides containing the same protospacer sequence followed by either a
TGG or TAG PAM (Figure 3-5b). Consistent with in vivo data, experiments
showed similar cutting rates of the NGG target for wtCas9 and hCas9.
Quantification of the cleavage products showed that hCas9 cleaved more of the
NAG target than wtCas9 over longer timescales (Figure 3-6d). Altogether, the
data presented in Figure 3 indicate that while there is a modest increase in the
NAG-targeting properties of hCas9, this cannot explain the rise in the number of
CRISPR-resistant colonies mediated by the I473F mutation (Figure 3-3c).

3.3.2. Hyper Cas9 promotes higher rates of spacer acquisition
A second hypothesis that could explain the increase in CRISPR-Cas
immunity conferred by hCas9 is, as explained above, a possible increase in the
frequency of spacer acquisition by the cells expressing this mutant. To test this, I
performed a comparison of the spacer repertoires acquired by cells harboring
wtCas9 or hCas9. I made two plasmid libraries, carrying the spacer acquisition
genes cas1, cas2 and csn2 and wtcas9 or hcas9, the tracrRNA gene and the S.
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pyogenes array of repeats and spacers preceded by a “barcode” sequence of 10
nucleotides 50 bp immediately upstream of the CRISPR array (Figure 3-7a).
Cells harboring each library were infected with phage ϕNM4γ4 and DNA from the
adapted cells was used to amplify the CRISPR array via PCR and collect
sequence information of all the new acquired spacers using next generation
sequencing. The primers used also amplify the barcode sequence (Figure 3-7a)
and therefore each new spacer sequence can be associated with a unique
barcode, allowing us to count how many times a given spacer was independently
acquired in each bacterial population. Over three million reads belonging to either
library were analyzed.
The frequency of reads corresponding to each acquired spacer sequence
was plotted according to its position in the ϕNM4γ4 genome (Figure 3-8a).
Analysis of the PAMs of the acquired spacers showed that over 99.5% of the
spacer reads contained the NGG sequence in both libraries (Figure 3-8b),
corroborating our in vivo data showing that hCas9 retained NGG PAM specificity.
In addition, I looked at the repertoire of unique different spacers independently of
the number of reads per sequence (Figure 3-8c). Consistent with our previous
finding that the PAM specificity of Cas9 is responsible for the PAM sequence of
the new protospacers, the hCas9 library showed a 5-fold increase in the
acquisition of spacers matching NAG-flanked targets. I also observed an
increase in the total number of different spacer sequences, from 1980 for wtCas9
cells to 2500 for the hCas9 sample.
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Figure 3-7. hCas9 Promotes Higher Rates of Spacer Acquisition . (a)
Schematic diagram of the S. pyogenes CRISPR locus showing the barcode and
primers (arrows) used to measure the number of independent spacer acquisition
events. (b) Cultures expressing WTCas9 or hCas9 were infected with fNM4g4
phage, and surviving cells were collected after 24 hr, had DNA extracted, and
were used as template for PCR of the CRISPR arrays. Amplification products
were separated by agarose gel electrophoresis (not shown), and the DNA of the
expanded CRISPR array was subject to MiSeq next-generation sequencing. The
number of barcodes for each spacer sequence across the phage genome,
normalized by the total number of spacer reads obtained, was plotted. (c) The
hCas9/WTCas9 frequency of independent acquisition events ratio for 1,938
common spacer sequences was plotted across the phage genome. The zone
where the ratio is greater than one is shown in gray. The red line shows the
average ratio. (d) Same as (b) but without phage infection; i.e., a measure of
acquisition of spacers derived from the host chromosome and resident plasmids.
(e) Pairwise competition between staphylococci expressing WTCas9 or hCas9.
The change in the relative frequency of cells carrying the hcas9 allele (y axis) is
plotted against the number of culture transfers (1 transfer/day, x axis).
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To calculate the frequency of acquisition of every spacer I divided the
number of different barcodes for a given spacer sequence by the total number of
reads. This value was plotted according to its position in the ϕNM4γ4 genome
(Figure 3-7b). The data show an increase in the frequency of acquisition in
hCas9 cells, with a 6-fold increase in the average frequency. For all spacer
sequences shared between the two libraries (1938 sequences were shared
between the 1980 and 2500 different sequences for wtCas9 and hCas9,
respectively), I calculated the ratio of unique adaptation events (i.e. number of
different barcodes) for hCas9 reads compared to wtCas9 (Figure 3-7c). I found
that more than 97% of the spacers were acquired more frequently in the hCas9
library (ratio > 1), with an average ratio of ~18. All together, these findings show
that hCas9 provides the host bacterium with more efficient spacer acquisition and
suggest that this is a major contribution to the enhanced CRISPR-Cas immunity
granted by hCas9.
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Figure 3-8. Analysis of next-generation sequencing results. (a) Data
presented in Figure 3-7b was plotted as the number of reads for each spacer
sequence across the phage genome, normalized by the total number of spacer
reads obtained. Spacers matching protospacers with NGG PAMs are shown in
blue, with NAG PAMs in yellow. (b) Quantification of the data shown in panel
a. (c) Quantification of the data shown in Figure 3-7b. (d) Alignment of Cas9
protein sequences belonging to type II CRISPR-Cas systems. Highlighted in
orange is the I473 residue. An equivalent residue is not found in some type II-B
and II-C systems. (e) Fraction (%) of staphylococci retaining the plasmid
harboring wtcas9 and hcas9 after 10 days of culture; with one transfer (1:100
dilution into fresh media) per day. Cells were plated in solid media with and
without chloramphenicol, an antibiotic that selects for cells harboring the
pCRISPR plasmid. The fraction of staphylococci carrying this plasmid was
obtained dividing the chloramphenicol-resistant cfu by the total cfu count. Data
are represented as mean ± SD of three representative biological replicates.
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3.4. Discussion
Here I performed random mutagenesis on the cas9 gene to identify
mutants with an expanded CRISPR-Cas response. Specifically, I looked for
mutants that would allow Cas9 to recognize not only NGG- but also NAGcontaining targets. I isolated a mutant, harboring an I473F substitution, that
displayed a modest increase in NAG-target recognition. More importantly, the
mutation increased the CRISPR-Cas immune response of the bacterial host by
more than two orders of magnitude, as measured by the number of CRISPRmediated bacteriophage resistant colonies obtained after phage infection. Due to
this hyper-activity in CRISPR immunity I named the mutant version of Cas9
hyper-Cas9, or hCas9. Deeper analysis of hCas9 revealed that it can perform
crRNA-guided cleavage of targets containing an NAG PAM better than wtCas9.
However, this improvement is minor and does not seem to contribute significantly
to the rise of a high number of CRISPR-mediated resistant cells. On the other
hand, upon phage infection bacteria expressing hCas9 are able to acquire many
more viral spacers than those expressing wtCas9. I hypothesize that this high
rate of spacer incorporation is the basis for the observed increase in the
CRISPR-mediated phage resistant colonies.
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At the molecular level, the mechanism by which the I473F mutation
enables this increase in spacer acquisition is not clear. I previously reported the
existence of a complex between the four Cas proteins encoded by the type II-A
CRISPR locus, namely Cas9, Cas1, Cas2 and Csn284. I hypothesized that these
complex functions in spacer acquisition, with Cas9 selecting sequences flanked
by NGG PAMs84 and Cas1 and Cas270,79 being involved in the integration of
these sequences into the CRISPR array. The precise role of Csn2 in spacer
acquisition remains to be elucidated. I thought that the I473F mutation could
affect the formation of the complex, since the mutated residue is located on Cas9
surface and could participate in its interaction with another Cas protein. The
substitution could enhance protein-protein interactions and either increase the
abundance or the stability of the complex, thus increasing the rate of spacer
acquisition. To test this, I incubated the four proteins along with a single-guide
RNA34 and subjected them to gel filtration to detect the formation of the complex.
However, I did not observe significant amounts of stable complexes neither in the
presence of wtCas9 nor hCas9. In wtCas9, the isoleucine residue is in direct
contact with bases of the tracrRNA (Figure 3-1d) that are equivalent to the nexus
in the single-guide RNA88. Specifically, nucleotide U59 of the tracrRNA inserts
into a hydrophobic pocket lined by I473 and its adjacent residues87. It is possible
that the bulkier phenylalanine residue could interfere with the tracrRNA:Cas9
association, affecting the involvement of Cas9 in the immunization step of the
CRISPR-Cas response. This hypothesis is supported by the wild-type phenotype
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of the I473A mutation (Figure 3-4), since the smaller alanine residue most likely
will not interfere with the tracrRNA interaction. Another mutation in a residue
close to I473, K500I, also seems to affect Cas9 target specificity, but not the rate
of spacer acquisition. Future work will explore the importance of this region in
Cas9 activity during the different phases of CRISPR-Cas immunity.
In a recent study89, the E. coli type I-E CRISPR-Cas adaptation machinery
has been repurposed as a recording device to store information (such as
environmental signals) in the form of spacers in the CRISPR array. Because the
adaptation frequency is relatively low, decoding requires deep sequencing of a
population of cells. This limits the number of stimuli that can be recorded. Using
hyperactive adaptation machinery such as hCas9 can boost the adaptation
frequency and thus the recording capacity of such synthetic devices. Moreover,
combined with introduction of sheared genomic DNA, the hyperactive CRISPR
adaptation machinery can be used to generate diverse and unbiased gRNA
libraries in vivo. I speculate that hCas9 is able to sample much larger genomes
then the type I-E Cas1-Cas2 complex
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Chapter IV.
Spacer Acquisition and Immunological
Diversity

Previous studies have shown that the abundance of each spacer in the
surviving population is highly uneven. However, the molecular mechanisms
underlying this bias are poorly understood. Here, I studied the factors that affect
the distribution of individual spacer sequences after phage infection of cells
harboring the type II-A CRISPR system from Streptococcus pyogenes. I show
that spacer patterns are established early during infection and correlate with
spacer acquisition rates, but not with spacer targeting efficiency. I also show that
the rate of spacer acquisition depends on unique sequence elements within the
spacer, which in turn determines the abundance of different spacers within the
adapted population. Our results elucidate a fundamental mechanism behind the
generation of immunological diversity during the type II CRISPR-Cas response.
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4.1. An uneven spacer distribution across the phage genome
In the type II-A CRISPR system from Streptococcus pyogenes, cleavage is
performed by the crRNA-guided nuclease Cas934, whose catalytic activity
depends on the recognition of a 5’-NGG-3’ protospacer adjacent motif (PAM)33,34
Cas9 contains a PAM-interacting domain to recognize this motif33,71 that is not
only required for target cleavage but also for the acquisition of spacers with the
appropriate PAM84.
Besides the presence of a functional PAM, the rules that govern spacer
acquisition in type II CRISPR-Cas systems are not completely understood.
Multiple studies have shown an uneven pattern of spacer acquisition, where
different spacer sequences have markedly different abundances within the
population of cells that survive phage infection40,84,90. This observation led to the
hypothesis that some spacers become overrepresented because they are more
effective at directing targeting and/or cleavage by Cas9 and therefore have a
selective advantage40. However, even when spacer acquisition was measured
within 30 minutes of infection, i.e. before the viral lytic cycle is completed and the
spacers cannot be selected for their abilities to guide DNA destruction, the
pattern of spacer acquisition is constricted to the viral region that is first injected
but with highly variable frequencies of acquisition for different spacers sequences
within this genomic location91. These data suggest that the abundance of a
spacer in the population of surviving bacteria can be independent of its targeting
properties and determined solely by its acquisition rate.
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Here I used the type II-A CRISPR system from Streptococcus pyogenes
expressed in Staphylococcus aureus RN4220 cells84 to investigate the
mechanisms behind the pattern of spacer acquisition when cells are infected with
the staphylococcal phage ϕNM4γ464,84. First, I determined that this pattern is
remarkably reproducible, with a set of spacer sequences consistently acquired
at high frequencies. By measuring spacer abundance early and late during
infection, I show that the frequency of individual spacers is mainly determined
at the onset of infection and that there is little selection of spacer sequences
thereafter. This led to the hypothesis that spacer abundance depends on the
rate of acquisition rather than enhanced Cas9 cleavage activity. I tested this on
selected spacer sequences at each end of the distribution spectrum by
performing targeting assays and quantifying CRISPR acquisition of spacerlength oligonucleotides. These experiments demonstrated that high and low
abundance spacers have similar targeting abilities but differ dramatically in
their efficiency of acquisition. I established that the intrinsic spacer sequence
dictates its acquisition rate, with the sequences proximal to the PAM being
most critical. Our studies reveal that, for type II-A systems, spacer acquisition
rates are fundamental to determine the distribution and diversity of the
CRISPR-Cas immune response.
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4.2. Spacer distribution is biased and reproducible
To analyze spacer distribution in the type II-A CRISPR system of S.

pyogenes (Figure 4-1a) I performed infection assays with lytic phage ϕNM4γ4,
as described previously92. DNA from surviving cells was used to amplify the
CRISPR array by PCR and perform next generation sequencing of newly
acquired spacers. I performed the infection in duplicate and obtained two libraries
of 2.52 and 2.28 million phage-mapping reads, respectively. Of all the possible
2,318 NGG-adjacent protospacers on the genome of ϕNM4γ4, 2,096 were
sampled in both libraries. The frequency of each spacer was normalized as
reads per million (RPM) and plotted across the phage genome (1 kb bins, Figure
4-1b). I observed a similar pattern of spacer distribution for each duplicate
experiment. To determine if the correlation is present not only in the groups of
spacers within each 1 kb bin, but also at the level of the individual spacer
sequences, I compared the RPM value for each of the 2,096 spacers (Figure 41c).
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Figure

4-1.

Acquired

spacer

sequences

display

a

consistent

distribution pattern. (a) Schematic diagram of the type II-A CRISPR system
from Streptococcus pyogenes. Arrows indicate the position of the PCR primers
used to check for spacer integration. (b) Average abundance (in reads per
million per 1-kb bins, RPM) of φNM4γ4 viral sequences incorporated as spacers
into the CRISPR array, mapped against location on the phage genome, in
duplicate (red and green traces). (c) Individual spacers common to the two data
sets in (b) were plotted with RPM values for replicate 1 on the x axis and
replicate 2 on the y axis. The dotted line represents the linear regression fit. Ten
spacers were color-coded based on their abundance (warm colors for low
abundance and cold colors for high abundance).
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We found a remarkable correlation of the spacer frequencies in both
replicas, particularly of the most abundant spacer sequences. I arbitrarily picked
five spacer sequences with high or low RPM and marked them with different
colors to follow their abundance over different experiments. This is an effort to
illustrate the relative consistency in the distribution of individual spacer
sequences, for example after mapping the spacers across the phage genome in
our replicates (Figure 4-2a-c). To test if this correlation extends to experiments
using other phages and type IIA CRISPR-Cas systems, I performed duplicate
infection experiments of cells containing the S. pyogenes type IIA system with the
phage ϕ8593 (Figure 4-2d), or cells harboring the type IIA (also known as
CRISPR317) from Streptococcus thermophilus with ϕNM4γ4 (Figure 4-2e).
Although I obtained fewer spacer reads in both cases (the efficiency of spacer
acquisition is reduced under these conditions84), a very strong correlation for
spacer abundance in the replicas was found. Altogether, these results indicate
that the abundance of individual spacer sequences within the population of
surviving cells is relatively constant during the type IIA CRISPR-Cas immune
response.
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Figure 4-2. Biased sampling of phage DNA protospacers is a feature
of other bacteriophages and type II CRISPR systems. (a), (b)
Abundance (in reads per million, RPM) of φNM4γ4 viral sequences incorporated
as spacers into the CRISPR array, mapped against location on the phage
genome, in duplicate (raw data for Figure 4-1b and 4-1c). (c) Overlap of data in
(a) and (b), zoomed on the first 5kb of the viral genome. Only spacers with RPM
> 5,000 are shown (d). RPM values of spacers sampled in two replicates during
infection with lytic phage φ85 of cells harboring the Streptococcus pyogenes
CRISPR system. (e) RPM values of spacers sampled in two replicates during
infection with φNM4γ4 of cells harboring the Streptococcus thermophilus type IIA CRISPR3 system.
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4.2.1. Effects of DNA cleavage efficiency on spacer distribution
In principle, the different but reproducible abundance of spacers could be
explained by two mutually non-exclusive forces that depend on their individual
sequences: their inherent frequency of acquisition and/or their efficiency of viral
targeting. To explore these possibilities, I compared the spacer distribution 30
minutes after infection, when the great majority of cells have not lysed yet (the
ϕNM4γ4 viral cycle takes ~ 40 minutes), with the distribution obtained after 16
hours of infection, a time during which the acquired spacers can be selected
against or for their targeting properties (Figure 4-3a).
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Figure 4-3. Spacer distribution due to initial acquisition is not
perturbed over the course of a live phage infection. (a) Diagram of
assay used to measure the effects of interference efficiency on spacer
abundance. (b) Average abundance (in reads per million per 1-kb bins, RPM) of
φNM4γ4 viral sequences incorporated as spacers into the CRISPR array,
mapped against location on the phage genome, in the early and late time point
libraries (red and green traces). (c), (d) Abundance (in reads per million, RPM)
of φNM4γ4 viral sequences incorporated as spacers into the CRISPR array,
mapped against location on the phage genome in the early and late time point
libraries (raw data for Figure 4-4). (e) Spacers ranked by decreasing fitness
(ratio of abundance in late time point divided by abundance in early time point)
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We analyzed over 0.72 million spacers for the early time point and 12.3
million spacers for the late time point, with 1,517 sequences shared between the
two libraries. I observed a strong correlation for the values obtained at both time
points for the frequency of each individual spacer (Figure 4-4a) and for their
overall distribution across the phage genome (Figure 4-3b-d). This result
suggests that spacer abundance is determined early after infection, and selection
throughout the recovery of CRISPR-adapted cells has a minimal impact on
shaping the spacer distribution. To explore this more directly, I calculated the
fold-increase in abundance from the early time point to the late time point for
each spacer. This value reflects the fitness of each sequence after its acquisition;
i.e., the positive or negative selection suffered by a spacer due to its targeting
abilities. I found that the fitness range of the entire spacer repertoire was narrow
and did not correlate with spacer abundance (Figure 4-4b). For example, our set
of highly abundant spacers had average finesses close to 1, even though they
were order of magnitudes more frequent than other spacers with similar finesses
(Figure 4-4b). Interestingly, I did not detect a strong positive selection for any
spacer sequence (the maximum fitness value was 3.3), but there were 14 that
displayed more than a 100-fold negative selection (Figure 4-4c, Figure 4-3e). On
average, the acquired spacers have a fitness value close to 1 (Figure 4-4c), with
approximately half of them displaying fitness higher than 1 and half lower than 1
(Figure 4-3e). These findings indicate that the relative abundance of spacer
sequences is determined at their time of acquisition, early during the CRISPRCas immune response, and remains relatively constant during the targeting
phase of CRISPR immunity.
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Figure 4-4. The spacer distribution pattern is established early
during infection. (a) Individual spacers common to the early and late time
point samples plotted as RPM values against each other. (b) Spacer abundance
in the live-phage sample (Figure 4-1) as a function of interference efficiency
(fitness = abundance in late / early time point). (c) The fold increase in
abundance in the late vs. early sample (fitness, y-axis) mapped across the phage
genome. The yellow curve represents average fitness in 1-kb bins.
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4.2.2. Effects of acquisition rates on spacer distribution
To test whether targeting efficiency affects the relative abundance of
individual spacer sequences, I performed a barcoded, phage-free spacer
acquisition experiment. For this I used a plasmid-based, modified type IIA
CRISPR-Cas system (Figure 4-5a) in which a single-repeat CRISPR array was
preceded by a random 10 nt sequence located 50 bp immediately upstream of
the repeat, a barcoding strategy I previously used to count independent
acquisition events92. In addition, expression of the cas1, cas2 and csn2 genes,
essential for spacer acquisition, is controlled by an anhydrotetracycline-inducible
promoter, allowing to turn on and off spacer integration84,91. Instead of using a
live lytic virus, cells harboring this engineered CRISPR-Cas locus were
transformed via electroporation with ϕNM4γ4 phage DNA, sheared into ~150 bp
fragments by sonication, in the presence of anhydrotetracycline. After two hours
the inducer was washed off, DNA was extracted from cells and the CRISPR loci
along with barcoded leaders were amplified by PCR (Figure 4-5a) and subjected
to next-generation sequencing. I analyzed 2.00 million spacer reads each with its
respective barcode that sampled almost all (2,274) of the existing protospacers
on the ϕNM4γ4 genome (Figure 4-6a-b). To test the barcoded system, I plotted
the relative abundance versus the number of different barcodes for each
individual sequence (Figure 4-6c). Assuming that different barcode sequences
in front of the same spacer are the result of independent events of integration,
this value reflects how many times a given spacer was acquired during
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Figure 4-5. Spacer abundance is determined by the rate of
acquisition. (a) Schematic diagram of the modified S. pyogenes CRISPR locus
showing the location of the leader barcodes and primers (arrows) used to
quantify the number of independent spacer acquisition events from sheared
phage DNA. (b) Overlap of spacer distribution during a live phage infection
(Figure 4-1) and number of barcodes as a measure of acquisition frequency, both
plotted in 1-kb bins. (c) Comparison between abundance of individual spacers
during a live phage infection and independent acquisition events from sheared
phage DNA.
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infection. I detected a strong correlation between the abundance of a spacer
and its number of barcodes, a result that validates the use of barcode count as
an absolute measure of the acquisition of a given spacer sequence present in
the ϕNM4γ4 genome.

We then compared the number of barcodes with the number of reads
obtained for each spacer sequence in the experiment using live phage
presented Figure 1. In this way I can determine how much of the spacer
distribution obtained after viral infection (measured as the average RPM of the
replica experiments of Figure 4-1) can be explained by the intrinsic rate of
acquisition of each viral spacer sequence (measured by the number of
barcodes obtained in Figure 4-6). First I compared the distribution patterns
across the ϕNM4γ4 genome (Fig. 4-5b). I found very similar distribution
patterns, with a conservation of most peaks and valleys in both curves (note
that the RPM and number of barcode values are intrinsically different and
therefore the curves do not overlap). Next, I plotted both values against each
other and found a good correlation, in which our ten selected spacers
maintained their low or high abundance, and with an r2 value of 0.536 (Fig. 45c). This indicates that the distribution of at least half of the spacers acquired
in response to viral infection can be explained by their intrinsic rate of
acquisition; i.e. independent of the targeting abilities of the spacer sequence.
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Figure 4-6. Oversampling of phage protospacers is due higher rates
of acquisition. (a) (b) Abundance (in reads per million, RPM) of spacers
incorporated into the CRISPR array, mapped against location on the phage
genome, following electroporation of sheared phage DNA (raw data for Figure 45). (c) Abundance of individual spacers following electroporation of sonicated
phage DNA plotted against barcodes as a measure of the number of times each
spacer was acquired.
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4.3. Analysis of spacer sequences that determine the rate of
acquisition
Our data suggests that the efficiency of the spacer acquisition process, i.e.
the selection and integration of a PAM-flanked phage sequence that happens
early during infection, is the most important factor to determine the abundance of
a spacer sequence during the CRISPR-Cas immune response. If this hypothesis
is correct, when comparing a high- and low-abundance spacer it would be
expected that (i) their ability to direct Cas9-mediated DNA cleavage should be
similar, and (ii) their rate of acquisition should be dramatically different. To test
these predictions, I selected two spacer sequences that were consistently overand under-represented (the “dark green” and “red” spacers, respectively, in
Figure 4-1c) in all our assays (Fig. 4-7a).
We tested the first prediction by comparing the efficiency of in vitro DNA
cleavage by Cas9 using each of these spacers as guides and I found similar
cleavage kinetics (Fig. 4-7b and Figure 4-8a-c). Second, I measured the cleaving
capacity of each of these spacers in vivo, through the quantification of the
reduction in phage propagation that they mediate (Fig. 4-7c). I did not detect
significant differences between the spacers, a result that demonstrates that not
only in vitro, but also in vivo, these sequences provide similar levels of defense.
Because the sequences I decided to follow in these assays reside in different
regions of the phage genome, which could be a variable affecting their targeting
ability91, I repeated these assays with two other sequences that overlap with
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each other but have markedly dissimilar abundances (“light blue” and “tan” in
Figure 4-1c, Figure 4-9a). Again, I found no differences in DNA cleavage in vitro
(Figures 4-8a,d,e and 4-9b) or in vivo (Fig. 4-9c). All these results corroborate the
prediction that DNA targeting does not dictate spacer abundance.

Figure 4-7. High and low abundance spacers have similar
interference efficiencies. (a) Sequences of a high abundance (Figure 4-1,
dark green) and low abundance (Figure 4-1, red) spacer, following infection of
CRISPR cells with live phage. (b) Quantification of in vitro cleavage of a 2-kb
phage target by various concentrations of Cas9 loaded with sgRNAs
corresponding to the two spacers in (a). (c) Phage propagation measured as the
number of plaque forming units (pfu) per ml of stock, on cells without CRISPR or
cells loaded with Cas9 and a spacer targeting either one of the phage
protospacers in (a).
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Figure 4-8. High and low abundance spacers have similar
interference efficiencies. (a) Location on the phage genome of the spacers
colored dark green, red, light blue and tan in Figure 4-1. (b) Agarose gels in
triplicate of in vitro cleavage products of 2-kb phage targets by various
concentrations of Cas9 loaded with sgRNAs corresponding to the four spacers in
(a). The tested Cas9 concentrations were 6.26, 12.5, 25, 50 and 100nM.
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Figure

4-9.

Partially

overlapping

spacers

can

provide

similar

interference efficiencies, in spite of highly dissimilar abundances.
(a) Sequence of two high abundance (Figure 4-1, light blue) and low abundance
(Figure 4-1, tan) overlapping spacers. (b) Quantification of in vitro cleavage of a
2-kb phage target by various concentrations of Cas9 loaded with sgRNAs
corresponding to the two spacers in (a). (c) Phage propagation measured as the
number of plaque forming units (pfu) per ml of stock, on cells without CRISPR or
cells loaded with Cas9 and a spacer targeting either one of the phage
protospacers in (a). (d) Relative acquisition rates (%) following electroporation of
a single dsDNA oligonucleotide containing both protospacers.
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To test the second prediction, that super-spacers have an intrinsic higher
rate of acquisition, I designed an assay to compare the relative frequency of
CRISPR incorporation of different sequences. I co-transformed staphylococci
carrying the engineered type IIA CRISPR-Cas locus used for the acquisition of
spacers from sheared phage DNA with annealed, dsDNA oligonucleotides at
equimolar concentrations. Transformation was followed by next-generation
sequencing of the amplified CRISPR array to quantify the relative frequency of
acquisition for each transformed oligonucleotide. First, I compared the acquisition
of the selected over- and under-represented sequence (“dark green” and “red”
sequences, respectively, in Figure 4-1c), using oligonucleotides containing only
the 30-nt spacer sequence followed by the 3-nt PAM (Figure 4-7a). I observed a
striking difference in the number of reads, with ~ 96 % of the reads from oligoderived spacers matching the highly abundant sequence (Fig. 4-10a).
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Figure 4-10. Spacer sequences affect their rate of acquisition.
Relative acquisition rates (%) of spacers following electroporation of various pairs
(a)(c) or a set of 10 (c) dsDNA oligonucleotides mixed equimolar ratios.
To corroborate this finding, I performed spacer-specific PCR after transformation
using each of the spacer sequences as reverse primers to amplify the CRISPR
array. Consistent with our next generation sequencing data, I was able to detect
a strong PCR product only when using the highly acquired spacer as reverse
primer (Fig. 4-11a). I repeated these assays using extended oligonucleotides
harboring additional (15-nt) phage sequences flanking the spacers and obtained
similar results (Figure 4-11a-c). In addition, I compared the frequency of
acquisition of another high- and low-abundance spacer pair (the “light green” and
“orange” spacers in Figure 1c, respectively), and observed the same differential
integration into the CRISPR array (Fig. 4-10a). Finally, I measured acquisition of
the two overlapping spacers with dramatically different abundances (Figure 4-9a)
and found that even when a single dsDNA oligonucleotide containing both
sequences is used, mostly the abundant spacer sequence is acquired (Figure 49d). Altogether, these experiments demonstrate that for a given spacer
sequence, its efficiency of acquisition but not its targeting capabilities, correlate
with its abundance in the population of CRISPR-resistant cells.
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Figure 4-11. Sequence determinants within the protospacer
sequence affect the rate of acquisition. (a) Qualitative PCR to assess the
integration of a low abundance (Figure 4-1, red) and high abundance (Figure 4-1,
dark green) spacer after electroporation of corresponding dsDNA
oligonucleotides mixed in a 1:1 molar ratio. The oligonucleotides tested were
33bp long (protospacer + PAM only) or 63bp long (15bp upstream + protospacer
+ PAM + 15bp downstream). Reverse primers anneal on the integrated spacers.
(b) Sequence of oligonucleotides containing the protospacers in (a) with 15bp
upstream and downstream of the protospacer swapped or not. (c) Relative
acquisition rates (%) of spacers in (b) following electroporation of pairs of dsDNA
oligonucleotides mixed equimolar ratios. (d) Unweighted probability Logo of the
top 1% protospacers generated using kpLogo (showing only 10bp upstream of
the PAM). Nucleotides shown on top were enriched, while the ones shown on the
bottom were depleted in the spacers used to create the logo. Enriched or
depleted consensus sequences are shown to the right.
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The above results suggest that there must be some element in the
sequence of super-spacers that increases their rate of acquisition. To test this, I
divided the sequence of the spacers into PAM-distal, middle and PAM-proximal
10-nt regions (Figure 4-10a) and swapped these regions in the super-spacer and
low abundance spacer sequences. Electroporation with different pairs of
swapped oligos, followed by next generation sequencing of expanded CRISPR
arrays revealed that the presence of the 10-nt PAM-proximal region of the superspacer was necessary and sufficient to ensure high levels of acquisition of a
dsDNA oligo (Figure 4-10a). Moreover, the addition of the 10-nt PAM-proximal
region of the “dark green” highly acquired spacer, but not the middle or PAMdistal sequences, was also sufficient to increase the frequency of acquisition of
the “orange” low-abundance spacer (Figure 4-10a). To corroborate these
findings, I co-transformed 10 different dsDNA oligonucleotides containing
different combinations of 10-nt regions of the “dark green” and “red” spacer
sequences (Figure 4-10b). Again, I found that dsDNA oligos containing the 10-nt
PAM-proximal sequence of the highly acquired spacer were integrated into the
CRISPR array at significantly higher frequencies than those having the same
region from the low-abundance spacer. Finally, due to the impossibility of testing
every acquired spacer via oligo transformation, I evaluated the importance of this
sequence within the entire set of acquired spacers. To do this, I used kpLogo94 to
look for a conserved motif in the PAM-proximal 10-nt sequence of either the most
abundant spacers (in the top 1 %, of average spacer reads in Fig. 1c). This
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analysis yielded two motifs, corresponding to the enriched and depleted
consensus within this sequence (Figure 4-11d). I appended these motifs to the
low abundance (“red”) spacer to check for their influence in spacer acquisition. I
found that the PAM-proximal motif derived from highly abundant spacers
dramatically increased spacer acquisition (Figure 4-10c). The overall results of
these

experiments

demonstrate

that

specific

DNA

sequences

located

immediately upstream of the PAM have important effects on the frequency of
acquisition of the 30-nt spacer determined by that PAM.
4.4. Discussion
Early studies of the type II CRISPR-Cas response to phage infection have
shown that the population of surviving bacteria has a diverse content of new
spacer sequences, some much more abundant than others40,90,91. In principle,
the abundance of a spacer should be determined by two factors: its frequency of
integration into the CRISPR array and its targeting capabilities95. Here I found
that the abundance of most spacers is determined early during infection, when
positive or negative selection for good or bad targeting, respectively, is still not a
factor at play. In addition, there is a strong correlation between the abundance of
most spacers acquired during infection with live phage and their abundance after
transformation with sheared phage DNA, again, when targeting is not required for
survival. Finally, I showed that the frequency of most spacers in the surviving
population correlates directly with their frequency of acquisition.
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The data presented here show that the spacer abundance that emerges
after the type II CRISPR-Cas immune response is basically determined shortly
after infection, depending mostly on the acquisition rate of each acquired
sequence and not on its properties as a guide for Cas9 DNA cleavage. This is
also the prediction of theoretical analysis95. Modeling of the CRISPR-Cas
immune response determined that high spacer acquisition probabilities will lead
to greater diversity in the spacer distribution, while strong selection of spacers
providing better phage clearance will tend to homogenize the population of
spacers in favor of the most effective one (“winner takes all” situation). Previous
studies in our lab that evaluated the effect of the concentration of CRISPRadapted cells on immunity91,96 could provide an explanation for such model for
the impact of spacer acquisition on their distribution. The results showed that at
very low concentrations of immune cells there is a marked effect on the recovery
of these immune cells after infection. In this situation, equivalent to low
acquisition rates, leads to the positive selection of spacers that are better at
targeting due to their position in the CRISPR array96 or because they guide Cas9
to the phage genome immediately after its injection91. On the other hand, when
CRISPR-immune cells have high concentrations, the targeting efficiency of the
spacers does not impact the host’s growth after phage addition. Although both of
these studies investigated single-spacer cultures, I believe that a similar scenario
can happen during the infection of naïve cultures that acquired multiple
(thousands) of new spacers. The high rate of acquisition of certain sequences
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would effectively create a high concentration of immune cells that will provide
most of the immunity to the population, and no further selection of these
sequences due to their targeting efficiency will take place.
Our findings showed that spacer abundance is mostly determined at the
acquisition stage of type II CRISPR-Cas immunity. The uneven distribution of
different spacer sequences could be in principle explained by the existence of
phage genomic regions that are better substrates for spacer acquisition. Indeed,
this is the case for the regions that first enter the host cell91 and is a possible
explanation for the clustering of highly abundant spacers from the 5’ end of the
ϕNM4γ4 genome (Figure 4-2a-b). However, even within this region (and also
close to the cos site in ϕ12γ391) there is a wide spectrum of spacer
abundance. Here I showed that one explanation for these different abundances
is the intrinsic frequency of acquisition of a given spacer sequence.
Mutagenesis analysis revealed that the 10-nt sequence at the PAM end of a
spacer is determinant for its frequency of acquisition and that there are
conserved nucleotides within this region critical for the acquisition process. The
molecular mechanisms behind this preferential acquisition are intriguing. The
current model of spacer acquisition by type II CRISPR-Cas systems involves
three steps: phage DNA is degraded by AddAB to create the spacer
substrates91,97, these are selected and processed by a Cas9-Cas1-Cas2-Csn2
complex84 and finally the processed spacer sequence is integrated by the
Cas1-Cas2 integrase into the CRISPR array98. Future experiments will
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investigate the impact of specific spacer sequences in the efficiency of these
steps. In summary, our study begins to uncover the rules that govern the
generation of immunological diversity during the type II CRISPR-Cas response to
phage infection, revealing that spacer acquisition, a unique feature of these
systems, is a key determinant to the structure of the surviving population.
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Chapter V.
Perspectives
CRISPR-Cas is a DNA-encoded, sequence-specific immune system that
protects bacteria and archaea against phages and other genetic elements. The
adaptive feature of CRISPR-Cas immune systems relies on their ability to
memorize DNA sequences from invading molecules (acquisition) and allows
them to rapidly adapt against new threats. While recent research has drastically
improved our understanding of adaptation, future studies will continue to address
outstanding questions about the molecular mechanisms and technological
applications of CRISPR, in general, and spacer acquisition, in particular.
Molecularly, the functions of Cas1 and Cas2, two signature proteins
present in all CIRSPR systems, have been thoroughly investigated. In the type I
CRISPR system of E. coli, the Cas1-Cas2 complex is bound to a partially
duplexed dsDNA (pre-spacer)79. The complex recognizes specific sequences
upstream the CRISPR array to ensure leader-polarized spacer integration. This
process is facilitated by host factors such as IHF (integration host factor)99,100.
Similar findings were reported in type II-A CRISPR system of Streptococcus
pyogenes96,101,102. Integration of the spacer into the arrays is mediated by the
integrase activity of Cas179 and the presence of a correct PAM in the pre-spacer
facilitates integration in the right orientation103.
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By contrast, little is known about the other Cas proteins involved in spacer
acquisition. In type I-C of Bacillus halodurans, Cas4 has been shown to enhance
the formation of functional memory by assisting PAM-compatible spacer
selection104. In type II, Csn2 and Cas9 form a complex with Cas1 and Cas284 and
are involved in adaptation5. Structural studies have revealed that Csn2 forms a
ring-like structure around DNA, suggesting that it might recruit other proteins
involved in spacer selection or integration63. In addition, the tracrRNA is also
required84, suggesting that the apo-Cas9 structure77, very different from holoCas971, does not have the correct conformation to participate in spacer
acquisition. In addition to destroying the invading virus, Cas9 specifies PAMflanking viral sequences during adaptation to ensure only functional spacers are
acquired. This is in contrast to type I, where the Cas1-Cas2 complex is
necessary and sufficient to direct incorporation of new spacers with correct
PAMs. Therefore, the motif is sensed by only one protein in type II (Cas9)89, but
by different protein complexes in type I: Cas1-Cas2 during acquisition and the
Cascade complex during interference105. Recognition of the PAM by the Cascade
leads to accelerated integration of new spacers with correct PAMs during primed
acquisition. By contrast, priming is yet to be shown to be a feature of type II
CRISPR systems. Future work will address these and other mechanistical and
molecular aspects of spacer acquisition in different CRISPR-Cas systems.
In recent studies89,106, the E. coli type I-E CRISPR-Cas adaptation
machinery has been repurposed as a recording device to store information (such
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as environmental signals) in the form of spacers in the CRISPR array. Because
the adaptation frequency is relatively low, decoding requires deep sequencing of
a population of cells. This limits the number of stimuli that can be recorded. Using
hyperactive adaptation machinery such as hCas9 can boost the adaptation
frequency and thus the recording capacity of such synthetic devices. Moreover,
combined with introduction of sheared genomic DNA, the hyperactive CRISPR
adaptation machinery is able to sample much larger genomes than the type I-E
Cas1-Cas2 complex and can be used to generate diverse and unbiased gRNA
libraries in vivo. Further optimization of CRISPR-based molecular recording
technologies, such as TRACE106, will enable high throughput parallel temporal
recordings of biological states, such as fluctuations in gene expression or
metabolite concentration.
Besides these direct applications of spacer acquisition, CRISPR has
emerged as a powerful DNA-editing technology used across all fields of
biomedical research. Furthermore, CRISPR is expected to have tremendous
contributions to agriculture and treatment of human diseases. In the U.S., the first
clinical trials of CRISPR to treat genetic disorders like beta-thalassemia and
sickle cell disease are expected to begin in 2018.
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Chapter VI.
Material and Methods
Bacterial strains and growth conditions
Cultivation of Staphylococcus aureus RN422072 was carried out in heart infusion
broth (BHI) at 37°C. Whenever applicable, media were supplemented with
chloramphenicol at 10 μg/mL, erythromycin at 10 μg/mL or spectinomycin at
250 μg/mL to ensure maintenance of pC194, pE194 and pLZ12 derived
plasmids, respectively, or 5 mM CaCl2 for phage adsorption.

Directed evolution of cas9
The cas9 gene was mutagenized at a low rate of 0-4.5 mutations/kb by error
prone PCR using GeneMorph II Random Mutagenesis Kit. The mutant cas9
amplicons were cloned into a backbone plasmid containing a spacer matching a
TAG-adjacent target on ϕNM4γ4. The library was subjected to soft-agar lytic
phage infection and surviving colonies were re-streaked on fresh plates. The
TAG-cleaving efficiency of surviving colonies was individually assessed by phage
propagation assays.

Spacer acquisition assay
Spacer acquisition assays of cells harboring the full CRISPR system of

Streptococcus pyogenes were performed as described previously, both in liquid
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and on plate84. For plate acquisition assays, overnight cultures were launched
from single colonies and diluted to equal optical densities. CRISPR arrays were
amplified by PCR with primer pairs L400-H050 or L400-H052 (Supplementary
table S3).

Bacterial growth curves
Overnight cultures were launched from single colonies and diluted 1:100 in BHI.
After 1 hour of growth, optical density at 600 nm (OD600) was measured for each
culture, and samples were brought to equal cell densities and loaded into 96-well
plates along with ϕNM4γ4 at MOI =1. Measurements were taken every 10
minutes for 24 hours.

Cas9 target cleavage assay
Cas9 was expressed and purified as previously described (Jinek et al., 2012).
The I473F Cas9 expression vector was cloned by around-the-horn mutagenic
PCR. crRNA and tracrRNA were transcribed using T7 RNA polymerase from
single-stranded DNA templates and hybridized as previously described34,67. L2
oligonucleotides (Supplementary table S3) were hybridized to generate the two
different target DNA duplexes and native PAGE-purified before 5’ radiolabeling
using [γ-32P]-ATP (Perkin-Elmer) and T4 polynucleotide kinase (New England
Biosciences). Cleavage assays were carried out essentially as previously
described (Sternberg et al., 2014). In brief, Cas9 and crRNA:tracrRNA were
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allowed to form an RNP complex before addition of target DNA. Final
concentration of RNP was 100 nM and target was 1 nM. Reactions were
incubated at room temperature, and aliquots were taken at 0.25, 0.5, 1, 2, 5, 10,
30, and 60 minutes and quenched by addition of an equal volume of 95%
formamide and 50 mM EDTA. Samples were run on 10% urea-PAGE, visualized
by phosphorimaging, and quantified using ImageQuant (GE Healthcare).
cleavage by Cas9 of various targets was assessed using the Guide-It Complete
sgRNA Sreening System from Clontech (Cat. No. 632636) with minor
modifications. Cas9 and the sgRNAs were pre-incubated for 5 min at 37C in
equimolar ratio and then diluted into the cleavage reaction to final concentrations
of 100, 50, 25, 12.5 and 6.25nM. All reactions contained 10nM of a phagederived PCR template with the target site. All reactions were stopped after
5 minutes by heat inactivation at 80C for 5 minutes and stored at -80C until ready
to be run on an agarose gel.

Phage Interference Assay
Overnight cultures were launched from single colonies. Serial dilutions of a stock
of phage φNM4γ464 were spotted on fresh soft heart infusion agar (HIA) lawns of
targeting cells containing chloramphenicol 10 μg/ml and 5 mM CaCl2. Plates
were incubated at 37 °C overnight and interference efficiency was measured in
plaque forming units (pfu).
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Acquisition from live phage
Acquisition from live phage in cells harboring the CRISPR system of

Streptococcus pyogenes (plasmid pWJ40) or CRISPR3 of Streptococcus
thermophilus (pRH200) was performed as described previously84. In Figure 4-3
and 4-4, plasmid pWJ40* containing randomized leader barcodes was used
instead of pWJ4092. The unweighted probability Logo of the top 1% protospacers
was generated using kpLogo94.

Acquisition from shredded phage DNA
Phage DNA was shredded by sonication to fragments of ~150bp as described91.
Following dialysis, 100μg of phage DNA was electroporated into competent S.

aureus cells carrying plasmids pRH317 and pRH318*. Cells were recovered for
2h in BHI supplemented with anhydrotetracycline at 1μg/μl.

Acquisition from dsDNA oligos
dsDNA substrates were obtained by annealing ssDNA oligos in Duplex Buffer
from IDT. Following dialysis, 100nm of each competing dsDNA substrate were
mixed and electroporated in competent S. aureus cells carrying plasmids
pRH223 and pRH24084. Cells were recovered for 2h in BHI supplemented with
anhydrotetracycline at 1μg/μl. Need to write the electroporated oligos for all
samples either here or in a table.
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High-throughput sequencing
Plasmid DNA was extracted from adapted cultures. 200 ng of plasmid DNA was
used as template for Phusion PCR to amplify the CRISPR locus with primer pairs
H370-H371 (Figure 4-1, 4-2d), H180-B153 (Figure 4-2e), H370-H366 (Figure 4-5,
early timepoint), H372-H366 (Figure 4-5, late timepoint) and H186-H366 (oligo
electroporation). Following gel extraction and purification of the adapted bands,
samples were subject to Illumina MiSeq (Figures 4-1, 4-2, 4-5, 4-6, 4-7) or
NextSeq (Figures 4-3, 4-4) sequencing. Data analysis was performed in Python:
first, all newly acquired spacer sequences were extracted from raw MiSeq
FASTA data files. Next, the frequency, number of different barcodes, the phage
target location, and the flanking PAM were determined for each unique spacer
sequence. Analysis was finished in Excel.

On-plate spacer acquisition assay
To detect individual adapted colonies on a plate, cells from overnight cultures
were mixed with phage at a m.o.i. value of 1 in top agar containing appropriate
antibiotic and 5 mM CaCl2. The mixture was poured on BHI plates with antibiotic
and incubated at 37 °C overnight. Subsequently, colonies that survived phage
infection were re-streaked on fresh BHI plates in order to remove contaminating
virus and dead cells. Plates were incubated at 37 °C overnight. To check for
spacer acquisition, individual colonies were resuspended in lysis buffer (250 mM
KCl, 5 mM MgCl2 50 mM Tris-HCl at pH 9.0, 0.5% Triton X-100), treated with 50
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ng μl−1 lysostaphin and incubated at 37 °C for 5 min, then 98 °C for 5 min.
Following centrifugation (16,000g), a sample of the supernatant was used as
template for TopTaq PCR amplification with primers L400 and H050. The PCR
reactions were analyzed on 2% agarose gels (Fig. 2-1a).

Spacer Acquisition Enrichment PCR
Overnight cultures launched from single colonies were diluted 1:1,000 into a
fresh 10-ml culture of BHI containing appropriate antibiotic and 5 mM CaCl2.
When the cultures reached D600 nm of 0.4, depending on the experiment, they
were either infected with phage MOI value of 1 (Fig. 2-1b) or induced with 1 μg
ml−1 anhydrotetracycline (Fig. 2-1c). After 16 h, plasmids carrying the CRISPR
systems were extracted using a slightly modified QIAprep Spin Miniprep Kit
protocol: the pelleted bacterial cells were resuspended in 250 μl buffer P1
containing 50 ng μl−1 lysostaphin and incubated at 37 °C for 1 h, followed by the
standard QIAprep protocol. 100 ng of plasmid DNA was used to amplify the
CRISPR locus using Phusion DNA Polymerase (New England Biolabs) with the
following primer mix: 3 parts JW8 and 1 part each of JW3, JW4 and JW5
(Extended Data Table 4). The following cycling conditions were used: (1) 98 °C
for 30 s; (2) (for 30 times) 98 °C for 10 s, 64 °C for 20 s, 72 °C for 10 s; (3) 72 °C
for 5 min. The PCR reactions were analyzed on 2% agarose gels. To sequence
individual spacers, the adapted bands were extracted, gel-purified and cloned via
Zero Blunt TOPO PCR Cloning Kit (Invitrogen). CRISPR loci of individual clones
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were checked for expansion of the arrays by PCR using the primers listed above
and sent for sequencing.

Phage adsorption assay
The phage adsorption assay was performed as described previously30 with
minor modifications. Cells were grown in BHI and 10 mM CaCl2 to a D600 nm
(OD600) of 0.4. The phage solution was prepared at 106 plaque-forming units
(p.f.u.) per ml and 100 µl of this was added to 900 µl of cells. The mixture was
incubated for 10 min at 37 °C to allow adsorption of the phage to the cellular
membrane. The mixture was centrifuged for 1 min at 16,000g and the number of
phage particles left in the supernatant was determined by phage titer assay.

Plasmid construction
Construction of pWJ40 was described elsewhere17. For the construction of
pC194-derived and pE194-derived plasmids, cloning was performed using
chemically competent S. aureus cells, as described previously17. The Δcas1
(pRH059), Δcas2 (pRH061) and Δcsn2 (pRH063) mutants were constructed by
one-piece Gibson assembly31 from pWJ40 using the pairs of primers H016–
H017, H018–H019, H020–H021, respectively (Extended Data Table 4). Plasmid
pRH087 containing the wild type cas genes of S. pyogenes was obtained by
inserting the first spacer of S. pyogenes (annealed primers H049 and H050
containing compatible BsaI overhangs) in pDB184 using BsaI cloning32. BsaI
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cloning was also used to construct pRH079 and pRH233 by inserting a ϕNM4γ4
targeting spacer (annealed primers H029 and H030) into pDB114 and pDB184,
respectively. Plasmid pRH200 harbours the wild-type CRISPR3 system from S.
thermophilus LMD-9 amplified with H168 and H169 from genomic DNA. The
fragment was inserted on pE194 via Gibson assembly using H166 and H167.
pRH213 was constructed by replacing Cas9Sp on pRH087 with Cas9St from
pRH200 using the primer pairs H232–H233 and H231–H234, respectively.
pRH214 was constructed by replacing Cas9St on pRH200 with Cas9Sp from
pRH087 using the primer pairs H227–H230 and H228–H229, respectively.
pGG32 was created by reducing the CRISPR locus of pWJ40 to a single repeat.
This was accomplished by ‘round the horn’ PCR33 using primers oGG82 and
oGG83, followed by blunt ligation. pRH228 was constructed by replacing Cas9Sp
on pGG32 with Cas9St from pRH200 using the primer pairs H232–H233 and
H231–H234, respectively. pRH223 was constructed as a three-piece Gibson
assembly combining TetR+ptet from pKL55-iTet (primers B534 and B616),
pE194 (primers B532 and B617) and the cas1, cas2, csn2 genes and the array
from pGG32 (primers H176–H177). pRH231 was constructed from pGG32 by
one-piece Gibson assembly with primers H289–H290. pRH234 contains Cas1
E220A and was constructed via one-piece Gibson assembly from pRH223,
respectively, using the primer pair H312–H313. pRH227 was constructed from
pGG32 via two sequential single-piece Gibson assemblies: first, D10A was
introduced with B337–B338 and second, H840A was introduced with B339–
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B340. pRH229 was constructed via one-piece Gibson assembly from pGG32
using the primer pair H276–H277. Plasmids pRH240, pRH241, pRH242, pRH243
and pRH244 were constructed by one-piece Gibson assembly with primers
H237–H238 from pGG32, pRH228, pRH227, pRH229 and pRH231, respectively.
pRH245 was constructed from pRH241 via two sequential single-piece Gibson
assemblies: first, D10A was introduced with H336–H337 and second, H847A
was introduced with H338–H339. Plasmid pRH317 was constructed by deleting
the CRISPR leader and array from pRH22384 via a one-piece Gibson assembly
reaction with primer pair JM126-JM127. Plasmid pRH318 was constructed by a
two-piece Gibson assembly reaction from pRH24084 and pLZ12 with primer pairs
H558-H559 and H555-H557, respectively. Plasmid pRH318* (containing
randomized leader barcodes) was constructed by a two-piece Gibson assembly
with primers pairs H378-H294 and H379-H293. Plasmid pRH248, pRH249,
pRH328 and pRH328 were constructed BsaI cloning as described in Heler
Nature with annealed oligo pairs H433-H434, H435-H436, H641-H642, and
H643-H645, respectively.

Isolation and sequencing of ϕNM4γ4
For the initial isolation of ϕNM4, supernatants from overnight cultures of S.
aureus Newman were filtered and used to infect soft agar lawns of TB4:: ϕNM1,2
double lysogens. A single plaque was picked and then plaque-purified in two
additional rounds of infection using TB4 soft agar lawns, and subsequently used
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to lysogenize TB4. For the resultant lysogen, specific primers were used to verify
the presence of ϕNM4 and the absence of ϕNM1,2 by colony PCR. High titer
lysates of ϕNM4 (∼1011 p.f.u. per ml) were then prepared from this lineage and
used for infection of TB4/pGG9 soft agar lawns harboring spacer 2B17. An
escaper plaque was picked and then plaque-purified in two additional rounds of
infection using TB4/pGG9 soft agar lawns. The resultant ϕNM4γ4 phage
exhibited a clear plaque phenotype and was used to prepare a high titre lysate
from which DNA was purified, deep sequenced, and assembled as described
previously. The full sequence of the ϕNM4γ4 has been deposited in GenBank
under accession number KP209285 and includes a 2,784 bp deletion
encompassing the C-terminal 80% of the ϕNM4 cI-like repressor gene.

Protein purification of Cas9
pMJ806 (wild-type Cas9) plasmid was obtained from Addgene. The proteins
were purified as described before6 with minor modifications as follows. The
proteins were expressed in E. coli BL21 Rosetta 2(DE3) codon plus cells (EMD
Millipore). Cultures (2 litres) were grown at 37 °C in Terrific Broth medium
containing 50 μg ml−1 kanamycin and 34 μg ml−1 chloramphenicol until the
D600nm reached 0.6. The cultures were supplemented with 0.2 mM isopropyl-1thio-β-D-galactopyranoside and incubation was continued for 16 h at 16 °C with
constant shaking. The cells were collected by centrifugation and the pellets
stored at −80 °C. All subsequent steps were performed at 4 °C. Thawed bacteria
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were resuspended in 30 ml of buffer A (50 mM Tris–HCl pH 7.5, 500 mM NaCl,
200 mM Li2SO4, 10% sucrose, 15 mM imidazole) supplemented with complete
EDTA free protease inhibitor tablet (Roche). Triton X-100 and lysozyme were
added to final concentrations of 0.1% and 0.1 mg ml−1, respectively. After 30
min, the lysate was sonicated to reduce viscosity. Insoluble material was
removed by centrifugation for 1 h at 16,200g in a Beckman JA-3050 rotor. The
soluble extract was bound in batch to mixed for 1 h with 5 ml of Ni2+Nitrilotriacetic acid-agarose resin (Qiagen) that had been pre-equilibrated with
buffer A. The resin was recovered by centrifugation, and then washed extensively
with buffer A. The bound protein was eluted step-wise with aliquots of IMAC
buffer (50 mM Tris-HCl pH 7.5, 250 mM NaCl, 10% glycerol) containing
increasing concentrations of imidazole. The 200 mM imidazole elutes containing
the His6-MBP tagged Cas9 polypeptide was pooled together. The His6-MBP
affinity tag was removed by cleavage with TEV protease during overnight dialysis
against 20 mM Tris-HCl pH 7.5, 150 mM KCl, 1 mM TCEP and 10% glycerol. The
tagless Cas9 protein was separated from the fusion tag by using a 5 ml SP
Sepharose HiTrap column (GE Life Sciences). The protein was further purified by
size exclusion chromatography using a Superdex 200 10/300 GL in 20 mM Tris
HCl pH 7.5, 150 mM KCl, 1 mM TCEP, and 5% glycerol. The elution peak from
the size exclusion was aliquoted, frozen and kept at −80 °C.
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Protein purification of Cas1
Plasmid pKW01 (wild-type Cas1) was constructed by through amplification of
pWJ40 as a template for polymerase chain reactions (PCRs) to clone Cas1 into
pET28b-His10Smt3 using the primers PS192 and PS193 (Extended Data Table
4). Full sequencing of cloned DNA fragment confirmed perfect matches to the
original sequence. The pKW01 plasmid was transformed into E. coli BL21 (DE3)
Rosetta 2 cells (EMD Millipore). Cultures were grown and protein was purified by
Ni-affinity chromatography step, as mentioned before in Cas9 purification. The
200 mM imidazole elutes containing the His10-Smt3 tagged Cas1 polypeptide
was pooled together. The His10-Smt3 affinity tag was removed by cleavage with
SUMO protease during overnight dialysis against 50 mM Tris-HCl pH 7.5, 250
mM NaCl, 20 mM imidazole and 10% glycerol. The tagless Cas1 protein was
separated from the fusion tag by using a second Ni-NTA affinity step. The protein
was further purified by size exclusion chromatography using a Superdex 200
10/300 GL in 20 mM Tris HCl pH 7.5, 500 mM KCl, 1 mM TCEP, and 5%
glycerol. The elution peak from the size exclusion was aliquoted, frozen and kept
at −80 °C.
Protein purification of Cas2
The sequence encoding Cas2 was PCR amplified with primers PS334 and
PS335 from pWJ40 and inserted into a pET-His6 MBP TEV cloning vector
(Addgene Plasmid number 29656) using ligation independent cloning (LIC).
Sequencing of the resultant plasmid (pPS059) confirmed the matches to the wild-
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type sequence. The protein was expressed and purified following the same
procedure as that for Cas9.

Protein purification of Csn2
Plasmid pPS060 was constructed by through amplification of pWJ40 as a
template for polymerase chain reactions (PCRs) to clone Csn2 into pET28bHis10Smt3 using the primers PS336 and PS337. Full sequencing of cloned DNA
fragment confirmed perfect matches to the original sequence. Csn2 was
expressed and purified following the same method as that of Cas1. Previously
Csn2 was shown to form a tetramer34. Protein concentrations for all the
purifications were determined by using the Bradford dye reagent with BSA as the
standard.

Protein purification of Cas9–Cas1–Cas2–Csn2 complex
pKW07 (His10-Cas9–Cas1–Cas2–Csn2) was constructed by amplification of
pWJ40 with primers PS199/PS202 and pET16b (Novagen) with primers
PS200/PS203, followed by Gibson assembly of the fragments. Full sequencing of
cloned DNA fragment was done to confirm perfect matches to the original
sequence. The proteins were expressed in E. coli BL21 Rosetta 2(DE3) codon
plus cells (EMD Millipore). Cultures were grown and protein was purified by Niaffinity chromatography step, as mentioned before in Cas9 purification with minor
modifications. The 200 mM imidazole eluates were dialysed overnight against 20
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mM Tris-HCl pH 7.5, 150 mM KCl, 1 mM TCEP and 10% glycerol and subjected
to mass spectrometry for the identification of the co-purifying proteins. pKW06
(Cas9–Cas1–Cas2–Csn2–His6) was constructed by amplification of pWJ40 with
primers PS204/PS205 and pET23a (Novagen) with primers PS206/PS207
(Extended Data Table 4), followed by Gibson assembly of the fragments. Full
sequencing of cloned DNA fragment was done to confirm perfect matches to the
original sequence. The proteins were expressed in E. coli BL21 Rosetta 2(DE3)
codon plus cells (EMD Millipore). Cultures were grown and protein was purified
by Ni-affinity chromatography step, as mentioned before in Cas9 purification with
minor modifications. The 200 mM imidazole eluates were dialysed overnight
against 20 mM Tris-HCl pH 7.5, 150 mM KCl, 1 mM TCEP and 10% glycerol. The
proteins were further purified using a 5 ml SP Sepharose HiTrap column (GE Life
Sciences), eluting with a linear gradient of 150 mM–1 M KCl.

Oligonucleotides Used
Name

Sequence

B337

GACGCTATTTGTGCCGATAGCTAAGCCTATTGAGTATTTC

B338

GAAATACTCAATAGGCTTAGCTATCGGCACAAATAGCGTC

B339

GGAAACTTTGTGGAACAATGGCATCGACATCATAATCACT

B340

AGTGATTATGATGTCGATGCCATTGTTCCACAAAGTTTCC

B532

CTTTTTCCGTGATGGTAACTGTTCATATTTATCAGAGCTCGTG

B534

GAGCTCTGATAAATATGAACAGTTACCATCACGGAAAAAGGTTATG

B616

TTATTTTAATTATGCTCTATCAA

B617

GAGTGATCGTTAAATTTATACTGC

H001

GGGCACTTTTTCACTCATTTTAGCTTCCTTAGCTCCTGAAAATC

H002

GGTGCCAGCCAATGATTTTTTTAAGGCAGTTATTGG

H003

GCTAAGGAAGCTAAAATGAGTGAAAAAGTGCCCGCC

H004

ACTGCCTTAAAAAAATCATTGGCTGGCACCAAGCAG
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H005

GCTAAGGAAGCTAAAATGATTGAACAAGATGGATTGCAC

H006

ACTGCCTTAAAAAAATCAGAAGAACTCGTCAAGAAGGCG

H007

GACGAGTTCTTCTGATTTTTTTAAGGCAGTTATTGGTGC

H008

ATCTTGTTCAATCATTTTAGCTTCCTTAGCTCCTG

H009

TCCATCTTGTTCAATCATTTTAGCTTCCTTAGCTCCTGAAAATC

H010

GAGAAAGAGGGTTAATGGAAGCCGGCGGCACCTCGCTAAC

H011

GTGCCGCCGGCTTCCATTAACCCTCTTTCTCAAGTTATCA

H012

GCTATATGCGTTGAACCGGAATTGCCAGCTGGGGCGCCCT

H013

GGTGCCGCCGGCTTCCATTCAGAAGAACTCGTCAAGAAGGCG

H014

ACGAGTTCTTCTGAATGGAAGCCGGCGGCACCTCGCTAAC

H015

CCAGCTGGCAATTCCGGTTCAACGCATATAGCGCTAGCAG

H016

AGGAGGTGACTGATGGGAGTTCCTGAATTTAGGATATGAG

H017

TAAATTCAGGAACTCCCATCAGTCACCTCCTAGCTGACTC

H018

TTAGGATATGAGTGAGGCTTTTGATGAATCTTAATTTTTC

H019

TTCATCAAAAGCCTCACTCATATCCTAAATTCAGGAACTC

H020

TTTGATGAATCTTAATAAAAATATGGTATAATACTCTTAA

H021

TTATACCATATTTTTATTAAGATTCATCAAAAGCCTCCCC

H022

AAACACGAATATACAGGAAGAATACACGATGTTGG

H023

AAAACCAACATCGTGTATTCTTCCTGTATATTCGT

H024

AAACAAAAACAAAAATGTTTTAACACCTATTAACGG

H025

AAAACCGTTAATAGGTGTTAAAACATTTTTGTTTTT

H026

TGACGAGTTCTTCTGATTTTTTTAAGGCAGTTATTGGTGCCC

H027

TGACGAGTTCTTCTGATTTTTTTAAGGCAGTTATTGGTGCCCTTA

H029

AAACAAAAATGTTTTAACACCTATTAACGTAGTATG

H030

AAAACATACTACGTTAATAGGTGTTAAAACATTTTT

H031

GAACTTTGAAATCGGCTCAGGAAAAGGCCATTTTACCCTT

H032

TTTAAAGGGTAAAATGGCCTTTTCCTGAGCCGATTTCAAA

H033

GAACTTTGAGATCGGTTCTGGTAAGGGCCACTTCACTCTC

H034

TTTAGAGAGTGAAGTGGCCCTTACCAGAACCGATCTCAAA

H035

GAACATATCACACAAAGATAAACAAAAGTATAATTATTTC

H036

TTTAGAAATAATTATACTTTTGTTTATCTTTGTGTGATAT

H037

GAACATATCGCACAAGGACAAGCAGAAGTACAACTACTTT

H038

TTTAAAAGTAGTTGTACTTCTGCTTGTCCTTGTGCGATAT

H039

AAACCCCAGTCGACACCAGCAAAGTATTCTTTGATG

H040

AAAACATCAAAGAATACTTTGCTGGTGTCGACTGGG

H041

AAACCCATTGCACCTCAAGTATCGATGACTGATTCG

H042

AAAACGAATCAGTCATCGATACTTGAGGTGCAATGG

H043

AAACAAAAACGTTTTGACGCCCATCAACGTCGTGTG

H044

AAAACACACGACGTTGATGGGCGTCAAAACGTTTTT

H045

AAACAAGAACGTTTTGACCCCGATCAATGTCGTATG
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H046

AAAACATACGACATTGATCGGGGTCAAAACGTTCTT

H047

AAACAAGAACGTGTTGACCCCGATCAATGTCGTCTG

H048

AAAACAGACGACATTGATCGGGGTCAACACGTTCTT

H049

AAACTGCGCTGGTTGATTTCTTCTTGCGCTTTTTG

H050

AAAACAAAAAGCGCAAGAAGAAATCAACCAGCGCA

H051

AAACTTATATGAACATAACTCAATTTGTAAAAAAG

H052

AAAACTTTTTTACAAATTGAGTTATGTTCATATAA

H053

AAACAGGAATATCCGCAATAATTAATTGCGCTCTG

H054

AAAACAGAGCGCAATTAATTATTGCGGATATTCCT

H055

AAACAGTGCCGAGGAAAAATTAGGTGCGCTTGGCG

H056

AAAACGCCAAGCGCACCTAATTTTTCCTCGGCACT

H057

AAACTAAATTTGTTTAGCAGGTAAACCGTGCTTTG

H058

AAAACAAAGCACGGTTTACCTGCTAAACAAATTTA

H059

AAACTTCAGCACACTGAGACTTGTTGAGTTCCATG

H060

AAAACATGGAACTCAACAAGTCTCAGTGTGCTGAA

H061

TTTTAGGAGGCAAAAATGGATAAGAAATACTCAATAGGCT

H062

CATCTAAAATATACTTCAGTCACCTCCTAGCTGACTCAAA

H063

CTAGGAGGTGACTGAAGTATATTTTAGATGAAGATTATTT

H064

GTATTTCTTATCCATTTTTGCCTCCTAAAATAAAAAGTTT

H065

GAT ATA ATG GGA GAT AAG ACG GTT C

H066

GGG ACC TCT TTA GCT CCT TG

H067

AAACAAATGTTTTAACACCTATTAACGTAGTATTGG

H068

AAAACCAATACTACGTTAATAGGTGTTAAAACATTT

H069

AAACAGATAAAAACAAAAATGTTTTAACACCTATTG

H070

AAAACAATAGGTGTTAAAACATTTTTGTTTTTATCT

H073

AAACAACAAAAATGTTTTAACACCTATTAACGTAGG

H074

AAAACCTACGTTAATAGGTGTTAAAACATTTTTGTT

H075

AAACTATTAACGTAGTATTGGAATCTGATGAATATG

H076

AAAACATATTCATCAGATTCCAATACTACGTTAATA

H077

AAACTATTTTTAGATAAAAACAAAAATGTTTTAACG

H078

AAAACGTTAAAACATTTTTGTTTTTATCTAAAAATA

H079

AAACGATAAAAACAAAAATGTTTTAACACCTATTAG

H080

AAAACTAATAGGTGTTAAAACATTTTTGTTTTTATC

H081

AAACTGTTTTAACACCTATTAACGTAGTATTGGAAG

H082

AAAACTTCCAATACTACGTTAATAGGTGTTAAAACA

H083

AAACAAAATGTTTTAACACCTATTAACGTAGTATTG

H084

AAAACAATACTACGTTAATAGGTGTTAAAACATTTT

H085

AAACTCATCTCTCGGTATATATAATCCAAGTTATTG

H086

AAAACAATAACTTGGATTATATATACCGAGAGATGA

H089

AAACAAAACAAAAATGTTTTAACACCTATTAACGTG
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H090

AAAACACGTTAATAGGTGTTAAAACATTTTTGTTTT

H091

AAACAAACAAAAATGTTTTAACACCTATTAACGTAG

H092

AAAACTACGTTAATAGGTGTTAAAACATTTTTGTTT

H093

AAACATGTTTTAACACCTATTAACGTAGTATTGGAG

H094

AAAACTCCAATACTACGTTAATAGGTGTTAAAACAT

H095

AAACCAAAAATGTTTTAACACCTATTAACGTAGTAG

H096

AAAACTACTACGTTAATAGGTGTTAAAACATTTTTG

H097

AAACACAAAAATGTTTTAACACCTATTAACGTAGTG

H098

AAAACACTACGTTAATAGGTGTTAAAACATTTTTGT

H099

TCTATTTATTATTAATTATTGGGTAATATTTTTTGAAGAG

H100

AAATATTACCCAATAATTAATAATAAATAGATTATAACAC

H101

GCTATTTTGAGAGGACAAGAAGACTTTTATCC

H102

GGATAAAAGTCTTCTTGTCCTCTCAAAATAGC

H103

GGAAGTCTGAAGAAACATTTACCCCATGG

H104

CCATGGGGTAAATGTTTCTTCAGACTTCC

H105

GACAAACTTTGATATAAATCTTCCAAATGAAAAAGTACTACC

H106

GGTAGTACTTTTTCATTTGGAAGATTTATATCAAAGTTTGTC

H107

CCATGATGATGGTTTGACATTTAAAGAAGAC

H108

GTCTTCTTTAAATGTCAAACCATCATCATGG

H109

GGGCGGCATAAGCTAGAAAATATCG

H110

CGATATTTTCTAGCTTATGCCGCCC

H111

GCAAGAAATAGGCAAAGGAACCGC

H112

GCGGTTCCTTTGCCTATTTCTTGC

H113

AAACTTTAGCGATATTAATTATGCTCGTAAGAATG

H114

AAAACATTCTTACGAGCATAATTAATATCGCTAAA

H115

AAACTTTATTTTGCGTTAGAATTGACACCTCAAGAG

H116

AAAACTCTTGAGGTGTCAATTCTAACGCAAAATAAA

H117

AAACCTTTAAATGTTTTAAAAGAATAGCATCATTG

H118

AAAACAATGATGCTATTCTTTTAAAACATTTAAAG

H119

AAACACAGGAATTGAGACACCTCAATATATACTTGCG

H120

AAAACGCAAGTATATATTGAGGTGTCTCAATTCCTGT

H121

AAACAAAATGCAAGAATTAAACTACCCACCATATG

H122

AAAACATATGGTGGGTAGTTTAATTCTTGCATTTT

H123

AAACCTAAGATAGCTAAAGCAATACGTGATGATGTG

H124

AAAACACATCATCACGTATTGCTTTAGCTATCTTAG

H125

AAACATTTATATCCGATCTTATACGAAGTAAAGAG

H126

AAAACTCTTTACTTCGTATAAGATCGGATATAAAT

H127

TTTATCCATAAATTCGTTAAAGTCTTTACG

H128

TTATTTTGAGGATTTATAATGATGCTAGAG

H129

ATGAGTTATAGATATATGAGAATGATACTTATGTTTGATATGC
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H130

ATTTGAGTCAGCTAGGAGGTGACTGATGATAGAGCTATCTAAATACAATATTTTAGT
G

H131

GTATCATTCTCATATATCTATAACTCATGATTTATAAAATGAATATTGCTTAATATTTG
G

H132

AAACAGGAATTGAGACACCTCAATATATACTTGCG

H133

AAAACGCAAGTATATATTGAGGTGTCTCAATTCCT

H134

AAACGTGCGAAAGATAGCAGACGAAGAAGGAATTG

H135

AAAACAATTCCTTCTTCGTCTGCTATCTTTCGCAC

H136

TTTGAGTCAGCTAGGAGGTGACTGATGAAGAGTAAAAAGCATCCTCAAATC

H137

TGTATTACTGCATTTATTAAGAGTACTCTAGCATCATTATAAATCCTCAAAATAATTA
AG

H138

GAGTACTCTTAATAAATGCAGTAATACAGGGG

H139

TCAGTCACCTCCTAGCTGACTC

H140

TAACAACTACTATAACCTCTAGGCTTATGCCACTCTTATCCATCAATC

H141

AGCATCATTATAAATCCTCAAAATAACTCGTAGACTATTTTTGTCTAAAAAATTTTG

H142

TTATTTTGAGGATTTATAATGATGCTAGAGG

H143

AAGCCTAGAGGTTATAGTAGTTGTTAAAT

H144

GAACACTTTTGCGCTGGTTGATTTCTTCTTGCGCTTTTT

H145

TTTAAAAAAGCGCAAGAAGAAATCAACCAGCGCAAAAGT

H146

GAGCAAGTTAACATTAAATTAGATAAAACT

H147

AGTTTTATCTAATTTAATGTTAACTTGCTC

H148

AATATTTGGCGTAGTATGAAAGATTTAATT

H149

AATTAAATCTTTCATACTACGCCAAATATT

H150

GAACATAGGTAGCCTTTATACGGTCCATAAACATGGGGAT

H151

TTTAATCCCCATGTTTATGGACCGTATAAAGGCTACCTAT

H152

GGAAGAAGACAAGAACCATGAACGTCATC

H153

GATGACGTTCATGGTTCTTGTCTTCTTCC

H154

GATGAAGTTGCTTATCGTGAGAAATATCC

H155

GGATATTTCTCACGATAAGCAACTTCATC

H156

CTTAGCGCATATGTTTAAGTTTCGTG

H157

CACGAAACTTAAACATATGCGCTAAG

H158

CACAAGTGTTTGGACAAGGCGATAG

H159

CTATCGCCTTGTCCAAACACTTGTG

H160

GTTGTCGATAATGGTGCTTCAGCTC

H161

GAGCTGAAGCACCATTATCGACAAC

H162

GTGATGAAACAGTTTAAACGTCGCC

H163

GGCGACGTTTAAACTGTTTCATCAC

H164

GCCAAGTTAATCACTAAACGTAAGTTTG

H165

CAAACTTACGTTTAGTGATTAACTTGGC
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H166
H167

GAAATGTGAGAAGGGACCTCTGATAAATATGAACATGATGAGTGATCG
GGACTCTTTTATCTCTACTCGTGCTATAATTATACTAATTTTATAAGGAGG

H168

AGTATAATTATAGCACGAGTAGAGATAAAAGAGTCCTTTGGATGATTCC

H169

TGTTCATATTTATCAGAGGTCCCTTCTCACATTTCAATACTAGACTC

H170

GCTAGTATTTTGTCAACGAATAATAAGAGG

H171

TTTTCTGTGATGATAAACGATTGCC

H172

GCGTTAAATCAGTTAGGTGAGG

H173

ATTAATTACTGATATTATAATGGCAGAGTG

H174

TATCGGCACAAATAGCGATGCCACTCTTATCCATCAATCC

H175

GGATAAGAGTGGCATCGCTATTTGTGCCGATATCTAAGCC

H176

TTGATAGAGCATAATTAAAATAAGATGCCACTCTTATCCATCAATCC

H177

GCAGTATAAATTTAACGATCACTCTAAAACCTCTCCAACTACCTCCC

H178

CCAATTTTCGTTTGATGTCTAAAAAATTTCGTAATCGCAC

H179

GAAATTTTTTAGACATCAAACGAAAATTGGATAAAGTGGG

H180

TCTGGTAGAAAAGATATCCTACGAG

H181

GAGCTTCCGAGACTGGTCTC

H182

NNNNNCAGCAAAATTTTTTAGACAAAAATAGTC

H183

NNNNNCAGAAGAAGAAATCAACCAGCGC

H184

NNNNNTCACAAAATTTTTTAGACAAAAATAGTC

H185

NNNNNTCAAAGAAGAAATCAACCAGCGC

H186

NNNNNGTCCAAAATTTTTTAGACAAAAATAGTC

H187

NNNNNGTCAAGAAGAAATCAACCAGCGC

H188

NNNNNAGTCAAAATTTTTTAGACAAAAATAGTC

H189

NNNNNAGTTAACCCTCTTTCTCAAGTTATC

H190

CCCCAGCGAATTTTGAAGAAGTTGTCGATAAAGGTGC

H191

CGACAACTTCTTCAAAATTCGCTGGGGTAATTGTTTCTTCAG

H192

ATTGCTCGTAAAAAAGACGCGGATCCAAAAAAATATGG

H193

CCACCATATTTTTTTGGATCCGCGTCTTTTTTACGAGC

H194

GAAGTCTGAAGAAACAATTACCGCAGCGGCTTTTGAAGAAGTTGTCG

H195

TCGACAACTTCTTCAAAAGCCGCTGCGGTAATTGTTTCTTCAGACTTCC

H196

AAGCTTATTGCTCGTAAAAAAGCCGCGGCTCCAAAAAAATATGGTGG

H197

CCACCATATTTTTTTGGAGCCGCGGCTTTTTTACGAGCAATAAGC

H198

TGAAAAAATCTTGACTTTTCGAATTCC

H199

AATACTCATAAAGCAAACTATGTTTTGG

H200

GGAATTCGAAAAGTCAAGATTTTTTCAATCTTCTCACG

H201

CCAAAACATAGTTTGCTTTATGAGTATTTTACGG

H202

CAATATTGTCAAGAAAACAGAAGTACAGAC

H203

TTAGCAACCACTAGGACTGAATAAGC

H204

GCCTGTCTGTACTTCTGTTTTCTTGAC
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H205
H206

GAAGTCTGAAGAAACATTTACCGCAGCGGCTTTTGAAGAAGTTGTCG
ATCGACAACTTCTTCAAAAGCCGCTGCGGTAAATGTTTCTTCAGACTTCC

H207

GGAAGTCTGAAGAAACAGCTACCCCATGG

H208

CCATGGGGTAGCTGTTTCTTCAGACTTCC

H209

AATCACGGATTGGATAGAGGAAAACC

H210

TTAACCCTCTCCTAGTTTGGCAAGG

H211

CTTGCCAAACTAGGAGAGGGTTAATCCATCACTGGTCTTTATGAAACACG

H212

GTTTTCCTCTATCCAATCCGTGATTTGTTTTCTTGACAATATTGACTTGG

H213

AAGTACAGACAGGCGGATTCTCC

H214

CAGTCACCTCCTAGCTGACTC

H215

TTGATTTGAGTCAGCTAGGAGGTGACTGACAATCTGTTACAGGCCTC

H216

CTTGGAGAATCCGCCTGTCTGTACTTCCTGTTCCTCAACTTTTTTCACAAC

H221

GATAAAGGTGCTTCAGCTCAATC

H222

AGACTTCCGAGTCATCCATGC

H223

GGTTTTGATAGTCCAACGGTAGC

H224

AAGCTTGTCCGAATTTCTTTTTGG

H225

GCCGCGGCTCCAAAAAAATATGGTGGTTTTGATAGTCC

H226

GCAGCGGCTTTTGAAGAAGTTGTCGATAAAGGTGC

H227

TAATGGCAGGTTGGAGAACAGTAGTC

H228

ACTACTGTTCTCCAACCTGCCATTAGTCACCTCCTAGCTGACTC

H229

AGATTTTTCAAATAAGGAGAAATGTTTGAAATCATCAAACTCATTATGGATTTAATTT
AAACTTTTTATTTTAGG

H230

ACATTTCTCCTTATTTGAAAAATCTAAATTTATAGAAATTATTATACGC

H231

AACTTTTTATTTTAGGAGGCAAAAAGCGTATAATAATTTCTATAAATTTAGATTTTTC
AAATAAGG

H232

TTTTGCCTCCTAAAATAAAAAGTTTAAATTAAATCCATAATGAG

H233

TGATGGCTGGTTGGCGTAC

H234

CAACAGTACGCCAACCAGCCATCAACCCTCTCCTAGTTTGGC

H235

GATATCGGCACAAATAGCTTAGATGCCACTCTTATCCATCAATCC

H236

AAGAGTGGCATCTAAGCTATTTGTGCCGATATCTAAGCC

H237

GGCGTACTGATGAAGATTATTTCTTAATAACTAAAAATATGG

H238

TTTAGTTATTAAGAAATAATCTTCATCAGTACGCCAACCAGCC

H239

TCAATTGGACTTGATATTATAGACCTTGCCAAACTAGGAG

H240

TTTGGCAAGGTCTATAATATCAAGTCCAATTGAGTATGGC

H241

AACAGTAGTCATTTTAGACAAGGATTATATTTTGATGCCC

H242

ATAATCCTTGTCTAAAATGACTACTGTTCTCCAACCTGCC

H243

NNNNNTCGCAAAATTTTTTAGACAAAAATAGTC

H244

NNNNNTCGAAGAAGAAATCAACCAGCGC
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H245

NNNNNAGCCAAAATTTTTTAGACAAAAATAGTC

H246

NNNNNAGCAAGAAGAAATCAACCAGCGC

H247

NNNNNCATCAAAATTTTTTAGACAAAAATAGTC

H248

NNNNNCATAAGAAGAAATCAACCAGCGC

H249

NNNNNGACCAAAATTTTTTAGACAAAAATAGTC

H250

NNNNNGACAAGAAGAAATCAACCAGCGC

H251

NNNNNACTCAAAATTTTTTAGACAAAAATAGTC

H252

NNNNNACTAAGAAGAAATCAACCAGCGC

H253

NNNNNCTGCAAAATTTTTTAGACAAAAATAGTC

H254

NNNNNCTGAAGAAGAAATCAACCAGCGC

H255

NNNNNTGACAAAATTTTTTAGACAAAAATAGTC

H256

NNNNNTGATAACCCTCTTTCTCAAGTTATC

H257

AAGCTTTATATAACTCTCTTGCA

H258

ATGGTAAAGCTTTTGTAAAAACCTG

H259

GCTCTAGAAGCTTCAAAGTTTTAC

H260

GCGAAAAGATAAACGAAAGCTTG

H261

CTTAGAAGCTTGTACTAAGCCG

H262

CTTCGACAGTAGCTTTAGTTGC

H263

CAGAAAAACAATAACAGAAGCTTGGAA

H264

CTTGTTGTTTAGTAAAAGCTTGAG

H265

NNNNNGGGCAAAATTTTTTAGACAAAAATAGTC

H266

NNNNNGGGAAGAAGAAATCAACCAGCGC

H267

GGAATTATTTTGAAGCTGAAGTCATG

H268

AAACAACCAAAAAAGGGAAGGGCTCGGTTGTACAG

H269

AAAACTGTACAACCGAGCCCTTCCCTTTTTTGGTT

H270

AAACAACCAAAAAAGGGAAGGGCTCGGTTGTATCG

H271

AAAACGATACAACCGAGCCCTTCCCTTTTTTGGTT

H272

CAATTGATCAAAAACGATATACGTCTAC

H273

ATATCGTTTTTGATCAATTGTTGTATC

H274

ATCGTAAACAATATACGTCTACAAAAGAAG

H275

TAGACGTATATTGTTTACGATCAATTGTTG

H276

TTGATCAAAAACAATATACGTCTACAAAAGAAG

H277

TAGACGTATATTGTTTTTGATCAATTGTTGTATCAA

H278

ORDERED. CHECK SEQUENCE

H279

GATGCCACTCTTATCCATCAATCC

H280

TTTTTATTTTAATTATGCTCTATCAATGATAGAGTGTC

H281

GATAGAGCATAATTAAAATAAAAAGCATATTAAACTAATTTCGG

H282

TGGATTGATGGATAAGAGTGGCATCTAAAACTTCTTTTGTAGACG

H283

TGCGACTACAAAATTTTTTAGACAAAAATAGTCTACGAGG

H284

TTTGTCTAAAAAATTTTGTAGTCGCACTATTTGTCTCAGC
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H285

TGCGAGTACAAAATTTTTTAGACAAAAATAGTCTACGAGG

H286

TTTGTCTAAAAAATTTTGTACTCGCACTATTTGTCTCAGC

H287

GTACAATTCTTGTGTTGCTTATTTTTGTCAATAGCGGAGC

H288

CAAAAATAAGCAACACAAGAATTGTACCGCCTCTTAATGG

H289

AGCGCTTGGGAGAAATTCAAAGAAATTTATCAGCC

H290

TTTCTTTGAATTTCTCCCAAGCGCTTTCAAAACGC

H291

TCCAAGTTATTTGCATGCTCC

H292

AAAGGTGGTGAAAAGAAATGCC

H293

GCAAAAATGGATAAGAAATACTCAATAGGC

H294

TATTGAGTATTTCTTATCCATTTTTGCCTCC

H295

AACACGCATTGATTTGAGTCAGC

H296

TCCTAGCTGACTCAAATCAATGCG

H297

AAACCGAATAACTCACGTTCCATTGAATACTGTGTG

H298

AAAACACACAGTATTCAATGGAACGTGAGTTATTCG

H299

AAACACGTTCCATTGAATACTGTGTAGGCATGTTAG

H300

AAAACTAACATGCCTACACAGTATTCAATGGAACGT

H302

TTGGAGCTCCCGCTGC

H303

GGATTGATGGATAAGAGTGGC

H304

ATATTTAAAAGCAGCGGGAGC

H305

GTTTTAGATGCCACTCTTATCC

H306

CGTTTTGCATGGATGACTCG

H307

TGATTGAGCTGAAGCACC

H308

TGCGATCACAAAATTTTTTAGACAAAAATAGTCTACGAGG

H309

TTTGTCTAAAAAATTTTGTGATCGCACTATTTGTCTCAGC

H310

TGCGATGACAAAATTTTTTAGACAAAAATAGTCTACGAGG

H311

TTTGTCTAAAAAATTTTGTCATCGCACTATTTGTCTCAGC

H312

GATATTATGGCACCATTTAGGCCTTTAGTGG

H313

AAAGGCCTAAATGGTGCCATAATATCGCTAGC

H314

TATATCATGGTTTGGCAAATTTTGATCCGAG

H315

ATCAAAATTTGCCAAACCATGATATAAATCC

H316

TTTTGCTAGCGCTATTATGGAACCATTTAGGCC

H317

TGGTTCCATAATAGCGCTAGCAAAATTGAACTG

H318

CGGACACCGCTGAGGCACGAAAAGCCTATCG

H319

GCTTTTCGTGCCTCAGCGGTGTCCGTCGGC

H320

GAGGAAGCAAAAGCCTATCGAAAATTTCGG

H321

ATTTTCGATAGGCTTTTGCTTCCTCAGCGGTG

H322

GAGGAACGAAAAGCCTATGCAAAATTTCGG

H323

ATTTTGCATAGGCTTTTCGTTCCTCAGCGG

H324

ATCCTGGCATTGATTAAGTCCTTAGGAG

H325

AAGGACTTAATCAATGCCAGGATTGTG
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H326

TTAGGAGTAAAAGTAGCAACGCAAAGTG

H327

TTGCGTTGCTACTTTTACTCCTAAGGAC

H328

TTAGGAGTAGAAGTAGAAACGCAAAGTG

H329

TTGCGTTTCTACTTCTACTCCTAAGGAC

H330

AATTTAATGAGGAACCCGAAGTGAAATCG

H331

TTTCACTTCGGGTTCCTCATTAAATTGAG

H332

AAACTTTTAAGCTATTCATTTTAAAAGGTCATATG

H333

AAAACATATGACCTTTTAAAATGAATAGCTTAAAA

H334

AAACATTTTAAGCTATTCATTTTAAAAGGTCATAG

H335

AAAACTATGACCTTTTAAAATGAATAGCTTAAAAT

H336

CATACTCAATTGGACTTGCTATTGGAACGAATAGTGTTGG

H337

CGTTCCAATAGCAAGTCCAATTGAGTATGGCTTAGTC

H338

GTAATTATGATATTGATGCTATTATTCCTCAAGC

H339

GAGGAATAATAGCATCAATATCATAATTACTTAATC

H340

AAACTGCCTATTTTTTTATGTTATAGCTAGCCTTG

H341

AAAACAAGGCTAGCTATAACATAAAAAAATAGGCA

H342

AAACAATTCCTTGAATCGAAAGGAGGTTAGCCTTG

H343

AAAACAAGGCTAACCTCCTTTCGATTCAAGGAATT

H344

AAACCGTGTAAAGACATATTAGATCGAGTCAAGGG

H345

AAAACCCTTGACTCGATCTAATATGTCTTTACACG

H346

AAACATACGTGTAAAGACATATTAGATCGAGTCAG

H347

AAAACTGACTCGATCTAATATGTCTTTACACGTAT

H348

AAACAAGACATATTAGATCGAGTCAAGGAGGTTTG

H349

AAAACAAACCTCCTTGACTCGATCTAATATGTCTT

H350

AAACAGACATATTAGATCGAGTCAAGGAGGTTTTG

H351

AAAACAAAACCTCCTTGACTCGATCTAATATGTCT

H352

AAACGACATATTAGATCGAGTCAAGGAGGTTTTGG

H353

AAAACCAAAACCTCCTTGACTCGATCTAATATGTC

H354

CCCCAACAAGAGAATTGGC

H355

CACCACCATAAACAACACAAGG

H356

CAAATGGGACATCTCGATGG

H357

GTCAGGACCTTTAGGTCATAGC

H358

NNNNNCAGTAGCTGAGACAAATAGTGCG

H359

NNNNNCAGCTCAACAAGTCTCAGTGTGC

H360

NNNNNGCTTAGCTGAGACAAATAGTGCG

H361

NNNNNGCTCTCAACAAGTCTCAGTGTGC

H362

NNNNNCAGAAAACAGCATAGCTCTAAAACG

H363

NNNNNCAGAAAACAGCATAGCTCTAAAACA

H364

NNNNNCAGAAAACAGCATAGCTCTAAAACT

H365

NNNNNCAGGGCTTTTCAAGACTGAAGTCTAG
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H366

NNNNNGCTAAAACAGCATAGCTCTAAAACG

H367

NNNNNGCTAAAACAGCATAGCTCTAAAACA

H368

NNNNNGCTAAAACAGCATAGCTCTAAAACT

H369

NNNNNGCTGGCTTTTCAAGACTGAAGTCTAG

H370

NNNNNGACAGGGGCTTTTCAAGACTG

H371

NNNNNGACGAAGAAATCAACCAGCGC

H372

NNNNNACTAGGGGCTTTTCAAGACTG

H373

NNNNNACTGAAGAAATCAACCAGCGC

H374

NNNNNCTGAGGGGCTTTTCAAGACTG

H375

NNNNNCTGGAAGAAATCAACCAGCGC

H376

NNNNNTGAAGGGGCTTTTCAAGACTG

H377

NNNNNTGAGAAGAAATCAACCAGCGC

H378

CAGGGGCTTTTCAAGACTGNNNNNNNNNNGAGACAAATAGTGCG

H379

CAGTCTTGAAAAGCCCCTG

H380

TTCAAGGTAAGTTTTGTCGTATCGTTCAATTTTATTCCGATCAGGCAATAGTTGAAC
TTT

H381

TGAAAAAGTTCAACTATTGCCTGATCGGAATAAAATTGAACGATACGACAAAACTTA
CCT

H382

TAGAATATGAGTTATAGATATATGAGAATGATACTTATGTTTGATATGCC

H383

CATTCTCATATATCTATAACTCATATTCTAAATTCAGGAATTTCCTCACC

H384

AAATGTAGAATGATAAAATAGAGATAAAAGAGTCCTTTGG

H385

GACTCTTTTATCTCTATTTTATCATTCTACATTTAGGCGC

H386

TTCTATAAATTTAGATTTTAGTATTGGGTAATATTTTTTGAAGAG

H387

TATTACCCAATACTAAAATCTAAATTTATAGAAATTATTATACGC

H388

TTCAAGGTAAGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAAC

H389

TGAAGTTTTGGGACCATTCAAAACAGCATAGCTCTAAAACTTACCT

H390

TTCATCCATTGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAAC

H391

TGAAGTTTTGGGACCATTCAAAACAGCATAGCTCTAAAACAATGGA

H392

TTCAGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACAATGGA

H393

TGAATCCATTGTTTTGGGACCATTCAAAACAGCATAGCTCTAAAAC

H394

TTCAGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACTTACCT

H395

TGAAAGGTAAGTTTTGGGACCATTCAAAACAGCATAGCTCTAAAAC

H396

TTCAGAATAACTCACGTTCCATTGAATACTGTGTAGG

H397

TGAACCTACACAGTATTCAATGGAACGTGAGTTATTC

H398

TTCAGAATAACTCACGTTCCATTGAATACTGTGTAGGCATGTTATAATCCACACCCT
TGC

H399

TGAAGCAAGGGTGTGGATTATAACATGCCTACACAGTATTCAATGGAACGTGAGTT
ATTC

H400
H401

TTC AGT TTT GGG ACC ATT CAA AAC AGC ATA GCT CTA AAA CTT ACC T
TGA AAG GTA AGT TTT AGA GCT ATG CTG TTT TGA ATG GTC CCA AAA C
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H402

NNNNNCAGAGGGGCTTTTCAAGACTG

H403

NNNNNCAGGAAGAAATCAACCAGCGC

H404

NNNNNTCAAGGGGCTTTTCAAGACTG

H405

NNNNNTCAGAAGAAATCAACCAGCGC

H406

NNNNNGTCAGGGGCTTTTCAAGACTG

H407

NNNNNGTCGAAGAAATCAACCAGCGC

H408

NNNNNAGTAGGGGCTTTTCAAGACTG

H409

NNNNNAGTGAAGAAATCAACCAGCGC

H410

TTCCCAAAATAAAGGAAGAGTTATTTACTTTGTTTTCAG

H411

AAGTAAATAACTCTTCCTTTATTTTGGGAAAAGGCTG

H412

CCAAAATAAAGAGAAAGTTATTTACTTTGTTTTCAGATAC

H413

ACAAAGTAAATAACTTTCTCTTTATTTTGGGAAAAGGCTG

H414

TTTGTTTTCACGTACATTTTCATATAATGGTAAAGAGATG

H415

TACCATTATATGAAAATGTACGTGAAAACAAAGTAAATAACTCTCTC

H416

AAAAACAGTTTGCAGAAATGATTTATTTACATGGTGAAAG

H417

TGTAAATAAATCATTTCTGCAAACTGTTTTTCCGTGACCG

H418

TATTTACATGGTAAAAGAAATAATTGTATTGCAAACTCCG

H419

TACAATTATTTCTTTTACCATGTAAATAAATCATTCGTGC

H420

TGTATTGCAAACTCCGATAAAAGACTTGTATTTCTTGGGG

H421

TACAAGTCTTTTATCGGAGTTTGCAATACAATTATTTCTTTCACC

H422

GTATTTCTTGGGAAGGCTTTTGATGAATCTTAATTTTTCC

H423

AGATTCATCAAAAGCCTTCCCAAGAAATACAAGTCTTTCATCGG

H424
H425

ACAATTGATCGTAAACAATATAGGTCTACAAAAGAAGTTTTAGATGCCAC
TTGTAGACCTATATTGTTTACGATCAATTGTTGTATCAAAATATTTAAAAGCAGC

H426

AAATATGGTGGTTTTGAAAGTCCAACGGTAGCTTATTCAGTCC

H427

TACCGTTGGACTTTCAAAACCACCATATTTTTTTGGATCCC

H428

AAACCGAAATCATACGCAAAAATATTCATGTTAAG

H429

TTAACATGAATATTTTTGCGTATGATTTCGCAAAA

H430

AAACGAAATCATACGCAAAAATATTCATGTTAACG

H431

GTTAACATGAATATTTTTGCGTATGATTTCCAAAA

H432

CCAAAATAAAGAGAAAGTTATTTACTTTGTTTTCACGTAC

H433

AAACAAACAGTGACAGAAACTATTGAGTACGAGGG

H434

AAAACCCTCGTACTCAATAGTTTCTGTCACTGTTT

H435

AAACAGAAAACAGTGACAGAAACTATTGAGTACGG

H436

AAAACCGTACTCAATAGTTTCTGTCACTGTTTTCT

H437

TTGTTTCCCAAAACACCTATACCTG

H438

ATTTTCAGGTATAGGTGTTTTGGG

H439

GGAAGTCTGAAGAAACAGCTACCCCATGGAATTTTGAAG
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H440

AAACTATTCAAATTGTTACTTCATAATCTTTTGTG

H441

AAAACACAAAAGATTATGAAGTAACAATTTGAATA

H442

AAACAAGCTAGGAAGATTTAACTTAATACCTAATG

H443

AAAACATTAGGTATTAAGTTAAATCTTCCTAGCTT

H444

AAACGAGCTAGGGAGTTTAACGGTATGGAAGAAGG

H445

AAAACCTTCTTCCATACCGTTAAACTCCCTAGCTC

H446

AAACACATGTAACAGAGAAAATGGACAGAGAGTTG

H447

AAAACAACTCTCTGTCCATTTTCTCTGTTACATGT

H448

AAACATGTCACTTATAACCAAATGTTCAAGAAATG

H449

AAAACATTTCTTGAACATTTGGTTATAAGTGACAT

H450

AAACCAAATGTTCAAGAAATGGAGTGAAGCATAAG

H451

AAAACTTATGCTTCACTCCATTTCTTGAACATTTG

H452

AAACTTCACTTAATTGACGCATATGATTTAACAAG

H453

AAAACTTGTTAAATCATATGCGTCAATTAAGTGAA

H454

AAACTAGCATACCTTGTGTTACGCGGTATGGGTAG

H455

AAAACTACCCATACCGCGTAACACAAGGTATGCTA

H456

AAACAAGAAGATGCTTATATAGAAAAATTCCTTAG

H457

AAAACTAAGGAATTTTTCTATATAAGCATCTTCTT

H458

AAACAGATACGTATGCACATTACACAAGGTATTAG

H459

AAAACTAATACCTTGTGTAATGTGCATACGTATCT

H460

AAACCTGGTGGTAGTCGTGCTACAAAGATTCCGTG

H461

AAAACACGGAATCTTTGTAGCACGACTACCACCAG

H462

AAACGTACAATCACTAATTTTGTTAGCAGTATTTG

H463

AAAACAAATACTGCTAACAAAATTAGTGATTGTAC

H464

AAACTCCGCCAATAAACTTATGTGTGTATGCCTTG

H465

AAAACTCCGCCAATAAACTTATGTGTGTATGCCTT

H466

AAACGACATCATCGCAACATGTTTAGCTACATCAG

H467

AAAACTGATGTAGCTAAACATGTTGCGATGATGTC

H468

AAACGCTTTTATGTTATAATTGCTTTTATATAGTG

H469

AAAACACTATATAAAAGCAATTATAACATAAAAGC

H470

AAACTTTTTAACTTCAGGTCGTTGATAATACTCTG

H471

AAAACAGAGTATTATCAACGACCTGAAGTTAAAAA

H472

AAACATGACTTTAGCATTCCCGTATAACAGTTTAG

H473

AAAACTAAACTGTTATACGGGAATGCTAAAGTCAT

H474

AAACCTTTTATATAGTAGGAGTGAACTATATAGCG

H475

AAAACGCTATATAGTTCACTCCTACTATATAAAAG

H476

AAACCCGTTATGGCCTAGAATCATATTGCTAAAAG

H477

AAAACTTTTAGCAATATGATTCTAGGCCATAACGG

H478

AAACTTATTTTGCGTTAGAATTGACACCTCAAGAG

H479

AAAACTCTTGAGGTGTCAATTCTAACGCAAAATAA
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H480

AAACTTATCGTGAGTGGGAGAAATATAAGCGAAAG

H481

AAAACTTTCGCTTATATTTCTCCCACTCACGATAA

H482

AAACGACAAATGCTATTCAACATTCAGTTAAAGAG

H483

AAAACTCTTTAACTGAATGTTGAATAGCATTTGTC

H484

AAACGCTAAAACAAAAGATTTTATTAAAGCAAGAG

H485

AAAACTCTTGCTTTAATAAAATCTTTTGTTTTAGC

H486

AAACTGATACATTAACATTTAGTAAATCATTACGG

H487

AAAACCGTAATGATTTACTAAATGTTAATGTATCA

H488

AAACTTGTTTATCGATTGGAGCATGCAAATAACTG

H489

AAAACAGTTATTTGCATGCTCCAATCGATAAACAA

H490

AAACAGTTGGATTTAGATGCAAACCCCGCTAAAAG

H491

AAAACTTTTAGCGGGGTTTGCATCTAAATCCAACT

H492

AAACATTACTTAACACACTGCTAACAGCTGCAATG

H493

AAAACATTGCAGCTGTTAGCAGTGTGTTAAGTAAT

H494

AAACGGATATTGTCGTTTTCCCGTCAAAGTATGGG

H495

AAAACCCATACTTTGACGGGAAAACGACAATATCC

H496

AGAGGTTGAACTACGTAAGAGG

H497

TTGTGGTGGATACTGTGCC

H498

TACGATAATACTTATTATTATGTATTTCGAGG

H499

TTTACTGACTTTGCAAAACGC

H500

GAGAAATATCAAAATGATGATGTG

H501

GACTGTTTCTCTCATTGTTGCG

H502

TTTTTTGTTATGATGTGTTACACATGC

H503

AAGGAAGATGTCTCCTGTGG

H504

GTGATGAAGAAGAAATATTTAAGATGG

H505

TGTTAGATGAAGGTATGAGC

H506

GATCTTGCAATGTCTTATGACC

H507

ATGTTTTAACCATATCTAAATCAGC

H508

AGGAAGACACTAATGAATAACCG

H509

GGTATGGATTTCAGTGTTATGATTACG

H510

CATGAATCGCACCGGC

H511

TACTGCAATGGCTCCTATAGC

H512

AAACAATTAGGTTTTATTACTAATAAAAATGATAG

H513

AAAACTATCATTTTTATTAGTAATAAAACCTAATT

H514

AAACGTTGGACTAATGGCGTTGCGCAACCTGGTTG

H515

AAAACAACCAGGTTGCGCAACGCCATTAGTCCAAC

H516

AAACCAAGCAGAAAAATGGTTTGACAATTCATTAG

H517

AAAACTAATGAATTGTCAAACCATTTTTCTGCTTG

H518

AAACACGGTTATTCAACTAATTCAAGAATTACAGG

H519

AAAACCTGTAATTCTTGAATTAGTTGAATAACCGT
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H520

AAGCAACAGGACAAGCACC

H521

GCGGCCTCTAATACGACTCACTATAGGGCATATTAGATCGAGTCAAGGGTTTTAGA
GCTAGAAATAGCA

H522

GCGGCCTCTAATACGACTCACTATAGGGAGACATATTAGATCGAGTCAGTTTTAGA
GCTAGAAATAGCA

H523

GCGGCCTCTAATACGACTCACTATAGGGAGATCGAGTCAAGGAGGTTTGTTTTAGA
GCTAGAAATAGCA

H524

GCGGCCTCTAATACGACTCACTATAGGGGATCGAGTCAAGGAGGTTTTGTTTTAGA
GCTAGAAATAGCA

H525

GCGGCCTCTAATACGACTCACTATAGGGATCGAGTCAAGGAGGTTTTGGTTTTAGA
GCTAGAAATAGCA

H526

AGCAGTAGGGATTATGACGG

H527

ATCAAATCAGACTGATCGCTC

H528

AAACACGCAGATTGTTTGAGTGGTTACGTCAAAAG

H529

AAAACTTTTGACGTAACCACTCAAACAATCTGCGT

H530

AAACTTTAGCGATATTAATTATGCTCGTAAGAATG

H531

AAAACATTCTTACGAGCATAATTAATATCGCTAAA

H532

AAACCTCTGATGACGAATTAGCTATCATAACTTCG

H533

AAAACGAAGTTATGATAGCTAATTCGTCATCAGAG

H534

AAACCATTTTAGATTTCAAAAGTTTAGTATCTATG

H535

AAAACATAGATACTAAACTTTTGAAATCTAAAATG

H536

AAACGTATCTCTATTGACACCAATTTCTTCAGAAG

H537

AAAACTTCTGAAGAAATTGGTGTCAATAGAGATAC

H538

AAACATAGGGATTTTACAAGTGTACTTACAAGTAG

H539

AAAACTACTTGTAAGTACACTTGTAAAATCCCTAT

H540

AAACGAAATTAACTTGAAGCATTTCAAAGAAAATG

H541

AAAACATTTTCTTTGAAATGCTTCAAGTTAATTTC

H542

AAACAGTAGCTACTGCATCTGCAAATACAATTTTG

H543

AAAACAAAATTGTATTTGCAGATGCAGTAGCTACT

H544

AAACGAATAACTCACGTTCCATTGAATACTGTGTG

H545

AAAACACACAGTATTCAATGGAACGTGAGTTATTC

H546

AAACTGAATATTCATCTCTCGGTATATATAATCCG

H547

AAAACGGATTATATATACCGAGAGATGAATATTCA

H548

AAACCCAGAAGTTATGATAGCTAATTCGTCATCAG

H549

AAAACTGATGACGAATTAGCTATCATAACTTCTGG

H550

AAACATGCTCCAATCGATAAACAATTAGATAAACG

H551

AAAACGTTTATCTAATTGTTTATCGATTGGAGCAT

H552

NNNNNGTCTCTGGTAGAAAAGATATCCTACGAG

H553

NNNNNTCATCTGGTAGAAAAGATATCCTACGAG

H554

NNNNNGTCCTCGTACAGTGAACCTTTTTCACC

H555

NNNNNTCACTCGTACAGTGAACCTTTTTCACC
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H556

AGTTCAACAAACGGGTCATAACCTGAAGGAAGATCTGG

H557

CAGAATCCACGAGATCTGTGCCAGTTCGTAATGTCTGG

H558

TACGAACTGGCACAGATCTCGTGGATTCTGTGATTTGG

H559

CCTTCAGGTTATGACCCGTTTGTTGAACTAATGGGTGC

H560

AAACGATTGAACAATAGATTGTCTAAAGTTGAGAG

H561

AAAACTCTCAACTTTAGACAATCTATTGTTCAATC

H562

AAACTGTGGGAAAGTGGAAGAACTGAACCTAGAAG

H563

AAAACTTCTAGGTTCAGTTCTTCCACTTTCCCACA

H564

AAACTTTGTTCAATGTTTCTAAAGGTTATCTCTTG

H565

AAAACAAGAGATAACCTTTAGAAACATTGAACAAA

H566

AAACACCTAGCGAATGTATAGCACTAAAAATAAAG

H567

AAAACTTTATTTTTAGTGCTATACATTCGCTAGGT

H568

AAACACAATCTATTGTTCAATCTGATTTCTTTTAG

H569

AAAACTAAAAGAAATCAGATTGAACAATAGATTGT

H570

AAACACTTGAAATTTTTTCGACCATACCCATTCTG

H571

AAAACAGAATGGGTATGGTCGAAAAAATTTCAAGT

H572

AAACATATGGAACCTCGATTTCGCTATCAAATTCG

H573

AAAACGAATTTGATAGCGAAATCGAGGTTCCATAT

H574

AAACTCCGTTTATTTTTAGTGCTATACATTCGCTG

H575

AAAACAGCGAATGTATAGCACTAAAAATAAACGGA

H576

AAACATAAAAGTGTAAAAACATTATATATAAGGAG

H577

AAAACTCCTTATATATAATGTTTTTACACTTTTAT

H578

AATAATTCTGTTGATTTCGTGCCACTGTGCGGG

H579

CCCGCACAGTGGCACGAAATCAACAGAATTATT

H580

ACTAAATTGTCCGTCAATAATTCTGTTGATTTCGTGCCACTGTGCGGGTGTGAATTG
CTTTCT

H581

AGAAAGCAATTCACACCCGCACAGTGGCACGAAATCAACAGAATTATTGACGGACA
ATTTAGT

H582

TGCACAAGCAGAAATGGAAGCTAAGAAAATTGG

H583

CCAATTTTCTTAGCTTCCATTTCTGCTTGTGCA

H584

TTCTAAGCCTGAATATGCACAAGCAGAAATGGAAGCTAAGAAAATTGGTGTAATTAT
TCCGTT

H585

AACGGAATAATTACACCAATTTTCTTAGCTTCCATTTCTGCTTGTGCATATTCAGGC
TTAGAA

H586

AACAACATCACCTATTTTAGGGTTAGCTTCTGG

H587

CCAGAAGCTAACCCTAAAATAGGTGATGTTGTT

H588

AGAATCCACCACTCTAACAACATCACCTATTTTAGGGTTAGCTTCTGGGAAATGTTC
ACGTAA

H589

TTACGTGAACATTTCCCAGAAGCTAACCCTAAAATAGGTGATGTTGTTAGAGTGGT
GGATTCT

H590

NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNAGG

H591

AATAATTCTGTTGATTTCGTGCCACTGTGC
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H592

GCACAGTGGCACGAAATCAACAGAATTATT

H593

GCACAGTGGCACGAAATCAACAG

H594

GTTTGGAGTATGTAGAAGTACAGTATACAACTGG

H595

CCAGTTGTATACTGTACTTCTACATACTCCAAAC

H596

GTTTGGAGTATGTAGAAGTACAGTATACAACTAT

H597

ATAGTTGTATACTGTACTTCTACATACTCCAAAC

H598

GTTTGGAGTATGTAGAAGTACAGTATACAAC

H599

GTTGTATACTGTACTTCTACATACTCCAAAC

H600

GTAGAAGTACAGTATACAACTGG

H601

CCAGTTGTATACTGTACTTCTAC

H602

GTAGAAGTACAGTATACAACTAT

H603

ATAGTTGTATACTGTACTTCTAC

H604

GTAGAAGTACAGTATACAAC

H605

GTTGTATACTGTACTTCTAC

H606

NNNNNGTCGGCTTTTCAAGACTGAAGTCTAG

H607

NNNNNCAGGGCTTTTCAAGACTGAAGTCTAG

H608

NNNNNAGTGGCTTTTCAAGACTGAAGTCTAG

H609

NNNNNTCAGGCTTTTCAAGACTGAAGTCTAG

H610

NNNNNGCTGGCTTTTCAAGACTGAAGTCTAG

H611

NNNNNCGAGGCTTTTCAAGACTGAAGTCTAG

H612

ATGAATGGATTGAAGAGAACACAGACGAACAGG

H613

CCTGTTCGTCTGTGTTCTCTTCAATCCATTCAT

H614

TTAACCAAGCAATAGATGAATGGATTGAAGAGAACACAGACGAACAGGACAGACTA
ATTAACT

H615

AGTTAATTAGTCTGTCCTGTTCGTCTGTGTTCTCTTCAATCCATTCATCTATTGCTTG
GTTAA

H616

AGAAATTATCGAATACTTAAATAAAAAAGCAGG

H617

CCTGCTTTTTTATTTAAGTATTCGATAATTTCT

H618

TTCCATTCCCTATAAAGAAATTATCGAATACTTAAATAAAAAAGCAGGAAAGCATTTT
AAACA

H619

TGTTTAAAATGCTTTCCTGCTTTTTTATTTAAGTATTCGATAATTTCTTTATAGGGAAT
GGAA

H620

ATGAATGGATTGAAGCTTAAATAAAAAAGCAGG

H621

CCTGCTTTTTTATTTAAGCTTCAATCCATTCAT

H622

AGAAATTATCGAATAAGAACACAGACGAACAGG

H623

CCTGTTCGTCTGTGTTCTTATTCGATAATTTCT

H624

ATGAATGGATTGAAGAGAACATAAAAAAGCAGG

H625

CCTGCTTTTTTATGTTCTCTTCAATCCATTCAT

H626

ATGAATGGATGAATACTTAAACAGACGAACAGG

H627

CCTGTTCGTCTGTTTAAGTATTCATCCATTCAT

H628

ATGAATGGATGAATACTTAAATAAAAAAGCAGG
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H629

CCTGCTTTTTTATTTAAGTATTCATCCATTCAT

H630

AGAAATTATCTGAAGAGAACACAGACGAACAGG

H631

CCTGTTCGTCTGTGTTCTCTTCAGATAATTTCT

H632

AGAAATTATCTGAAGAGAACATAAAAAAGCAGG

H633

CCTGCTTTTTTATGTTCTCTTCAGATAATTTCT

H634

AGAAATTATCGAATACTTAAACAGACGAACAGG

H635

CCTGTTCGTCTGTTTAAGTATTCGATAATTTCT

H636

TTCCATTCCCTATAAATGAATGGATTGAAGAGAACACAGACGAACAGGAAAGCATT
TTAAACA

H637

TGTTTAAAATGCTTTCCTGTTCGTCTGTGTTCTCTTCAATCCATTCATTTATAGGGAA
TGGAA

H638

TTAACCAAGCAATAGAGAAATTATCGAATACTTAAATAAAAAAGCAGGACAGACTAA
TTAACT

H639

AGTTAATTAGTCTGTCCTGCTTTTTTATTTAAGTATTCGATAATTTCTCTATTGCTTG
GTTAA

H641

AAACATGAATGGATTGAAGAGAACACAGACGAACG

H642

AAAACGTTCGTCTGTGTTCTCTTCAATCCATTCAT

H643

AAACAGAAATTATCGAATACTTAAATAAAAAAGCG

H644

AAAACGCTTTTTTATTTAAGTATTCGATAATTTCT

H645

ATGAATGGATTGAAGAGAACACAGACGAACATT

H646

AATGTTCGTCTGTGTTCTCTTCAATCCATTCAT

H647

TTAACCAAGCAATAGATGAATGGATTGAAGAGAACACAGACGAACATTACAGACTA
ATTAACT

H648

AGTTAATTAGTCTGTAATGTTCGTCTGTGTTCTCTTCAATCCATTCATCTATTGCTTG
GTTAA

H649

AGAAATTATCGAATACTTAAATAAAAAAGCATT

H650

AATGCTTTTTTATTTAAGTATTCGATAATTTCT

H651

TTCCATTCCCTATAAAGAAATTATCGAATACTTAAATAAAAAAGCATTAAAGCATTTT
AAACA

H652

TGTTTAAAATGCTTTAATGCTTTTTTATTTAAGTATTCGATAATTTCTTTATAGGGAAT
GGAA

H653

TTCCATTCCCTATAAAGAAATTATCGAATACTTAAATAAAAAAGCAGGGGAGGGGTT
TAAACA

H654

TGTTTAAACCCCTCCCCTGCTTTTTTATTTAAGTATTCGATAATTTCTTTATAGGGAA
TGGAA

H655

CACATCAATTAGTAAGACGCCAAAAGTAACAGG

H656

CCTGTTACTTTTGGCGTCTTACTAATTGATGTG

H657

ATAATAATGAACATGTCTTGTCACAGTTTCAGG

H658

CCTGAAACTGTGACAAGACATGTTCATTATTAT

H659

ATGAATGGATTGAAGAGAACCAAAAGTAACAGG

H660

CCTGTTACTTTTGGTTCTCTTCAATCCATTCAT

H661

AGAAATTATCGAATACTTAATCACAGTTTCAGG

H662

CCTGAAACTGTGATTAAGTATTCGATAATTTCT
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H663

NNNNNCCCCAAAATTTTTTAGACAAAAATAGTC

H664

NNNNNAAACAAAATTTTTTAGACAAAAATAGTC

H665

NNNNNTTTCAAAATTTTTTAGACAAAAATAGTC

H666

NNNNNAGTCCAAAATTTTTTAGACAAAAATAGTC

H667

NNNNNCTGACAAAATTTTTTAGACAAAAATAGTC

H668

ATAATAATGAACATGTCTTGACAGACGAACAGG

H669

CCTGTTCGTCTGTCAAGACATGTTCATTATTAT

H670

ATAATAATGATGAAGAGAACTCACAGTTTCAGG

H671

CCTGAAACTGTGAGTTCTCTTCATCATTATTAT

H672

ATGAATGGATACATGTCTTGTCACAGTTTCAGG

H673

CCTGAAACTGTGACAAGACATGTATCCATTCAT

H674

ATGGATTGAAGAGAACACAGACGAAC

H675

GTCTGTGTTCTCTTCAATCCATTCAT

H676

ATTATCGAATACTTAAATAAAAAAGC

H677

TTTTATTTAAGTATTCGATAATTTCT

H678

ATGGATTGAAGAGAACATAAAAAAGC

H679

TTTTATGTTCTCTTCAATCCATTCAT

H680

ATGGATGAATACTTAAACAGACGAAC

H681

GTCTGTTTAAGTATTCATCCATTCAT

H682

ATTATCTGAAGAGAACACAGACGAAC

H683

GTCTGTGTTCTCTTCAGATAATTTCT

H684

ATGGATGAATACTTAAATAAAAAAGC

H685

TTTTATTTAAGTATTCATCCATTCAT

H686

ATTATCTGAAGAGAACATAAAAAAGC

H687

TTTTATGTTCTCTTCAGATAATTTCT

H688

ATTATCGAATACTTAAACAGACGAAC

H689

GTCTGTTTAAGTATTCGATAATTTCT

H690

AAAGGATACGTGTAAAGACATATTAGATCGAGTCAAGGAGGTTTTG

H691

CAAAACCTCCTTGACTCGATCTAATATGTCTTTACACGTATCCTTT

H692
H693
H694
H695

AAAGGATACGTGTAAAGACATATTAGATCGAGTCAAGGAGGTTTTGGGGAAGTG
CACTTCCCCAAAACCTCCTTGACTCGATCTAATATGTCTTTACACGTATCCTTT
CCTCTAATACGACTCACTATAGGTGAAGAGAACACAGACGAACGTTTAAGAGCTAT
GC
CCTCTAATACGACTCACTATAGGAATACTTAAATAAAAAAGCGTTTAAGAGCTATGC

H696

AACTGCTACTTGTTGGAGC

H697

TTATCTCTTGTAGCAAACGTGG

H698

TGGCGTTCAAGAACTTATGG

H699

TACTCGTAACCATTCGGGTG
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H700

TATAAAGAAATTATCGAATACTTAAACCGATCAGTAGGAAAGC

H701

GCTTTCCTACTGATCGGTTTAAGTATTCGATAATTTCTTTATA

H702

TATAAAGAAATTATCGAATACTTAATTAATGACTAAGGAAAGC

H703

GCTTTCCTTAGTCATTAATTAAGTATTCGATAATTTCTTTATA

JW3

AAAACAGCATAGCTCTAAAACG

JW4

AAAACAGCATAGCTCTAAAACA

JW5

AAAACAGCATAGCTCTAAAACT

JW8

GGCTTTTCAAGACTGAAGTCTAG

L400

CGAAATTTTTTAGACAAAAATAGTC

oGG82

AACATTGCCGATGATAACTTGAG

oGG83

GTTTTGGGACCATTCAAAACAGCATAGCTCTAAAACCTCGTAG

PS192

CGCGGATCCATGGCTGGTTGGCGTACTGTTGTGG

PS193

CGCCTCGAGTCATATCCTAAATTCAGGAACTCC

PS199
PS200
PS202
PS203
PS204
PS205
PS206
PS207

CGAGCATATGACGACCTTCGATATGATCGGCAATGTTGAATGGAGACCATTC
GAATGGTCTCCATTCAACATTGCCGATCATATCGAAGGTCGTCATATGCTCG
CATCATCATCATCATCACAGCAGCGGCATGGATAAGAAATACTCAATAGG
CCTATTGAGTATTTCTTATCCATGCCGCTGCTGTGATGATGATGATGATG
CGACAAGCTTGCGGCCGCACTCGAGCTTTTTATTTTAGGAGGCAAAAATG
GGATCTCAGTGGTGGTGGTGGTGGTGTACCATATTTTTAGTTATTAAGAAATAATC
GATTATTTCTTAATAACTAAAAATATGGTACACCACCACCACCACCACTGAGATCC
CATTTTTGCCTCCTAAAATAAAAAGCTCGAGTGCGGCCGCAAGCTTGTCG

PS284

GCTAGCGATATTATGGCACCATTTAGGCCTTTAG

PS285

CTAAAGGCCTAAATGGTGCCATAATATCGCTAGC

PS334

TACTTCCAATCCAATGCAATGAGCTATCGCTATATG

PS335

TTATCCACTTCCAATGTTATTATTAGCTTTCATCAAAGGC

PS336

CGCGGATCCATGAACCTGAACTTTAGCCTGCTGG

PS337

CGCCTCGAGTTACACCATATTTTTGGTAATCAG

PS354

GTTCCTGAATTTAGGATATGAAACATTGCCGATCATATCGAAGG

PS355

CCTTCGATATGATCGGCAATGTTTCATATCCTAAATTCAGGAAC
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